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Abstract
The aims of my work were: a) to generate reagents (recombinant protein and antibodies) 
useful to identify MSF as a possible marker for TAMs in human tumours; b) to 
characterise the biological properties of MSF. MSF is a soluble oncofoetal isoform of 
human fibronectin 1, identical to the N-terminus portion of fibronectin and characterized 
by the presence of a unique 10 amino acids long sequence in the C-terminus end. MSF is 
expressed by epithelial and stromal cells during foetal development and in cancer patients, 
but not by adult normal cells. Our group found a selective expression of MSF by M2- 
polarized human macrophages and M2-like tumor-associated macrophages (TAMs). 
TAMs are major inflammatory cells infiltrating tumors, they support tumour growth and 
are associated to poor prognosis.
These findings suggest that MSF could be a potential marker for tumor progression 
associated to M2-like polarization of TAM and a promising target for anti-cancer therapy. 
Human MSF has been expressed in CHO cells and purified by affinity chromatography. 
Recombinant MSF has a motogenic effect on cancer cell lines, human monocytes and 
murine peritoneal macrophages. Different levels of MSF expression were observed in 
human cancer cell lines and correlate with its motogenic effect. In vivo experiments 
showed that tumors derived from MSF-expressing cells had an higher growth rate 
compared to tumors derived from control cells. We also developed a monoclonal antibody 
(MoAbElO) recognizing human MSF. A initial characterization on human tumour tissues 
(lung, breast, colon) showed MSF expression in tumor cells as well as stromal cells. In 
particular MSF expression is associated to M2-like TAM. Given that TAMs are promising 
target for anticancer therapy, the possibility to identify M2 polarized cells would be of 
considerable interest and further studies will be necessary to define the importance of MSF 
in the context of human tumours.
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LIST OF ABBREVIATIONS
Ab Antibody
BSA Bovine Serum Albumin
CCL- CC-chemokine
CCR- CC-chemokine receptor
CLR C-Type Lectin Receptor
CTL Cytotoxic T Lymphocytes
CXCL- CXC-chemokine
CXCR- CXC-chemokine receptor
ECM Extra Cellular Matrix
ED-A Extra-Domain A Fibronectin
ED-B Extra-Domain B Fibronectin
EGF Epidermial Growth Factor
ELISA Enzyme-Linked Immunosorbent Assay
FGF F ibroblast Growth F actor
FCS Fetal Calf Serum
FN Fibronectin
Gel-BD Gelatin-Binding Domain of Fibronectin
HNSCC Head and Neck Squamous Cell Carcinoma
IFN-y Interferon- y
IgG Immunoglobulin
IL- Interleukin
kDa kiloDalton
LPS Lypopolysacharide
M l Calssically Activated Macrophages
M2 Alternatively Activated Macrophages
M-CSF Macrophage- Colony Stimulating Factor
MDSC Myeloid-Derived suppressor Cell
MHC Mayor Hystocompatibility Complex
MMP Matrix Metalloproeinase
MSF Migration stimulating Factor
NF-kB Nuclear F actor kappa B
NK Natural Killer
NKT Natural Killer T
NLR Nod-Like Receptor
PAMP Pathogen-Associated Molecular Pattern
PBS Phosphate Buffered Saline
PMN Polymorphonuclear Leukocytes
PRR Pattern Recogniiton Receptor
RAG Recombinant-Activation Gene Knock-Out
RLR RIG-I-Like Receptor
SD Standard Deviation
SE Standard Error
STAT3 Signal Transducer and Activator of Transcription 3
SPARC Secreated Protein Acidic and Rich in cystein
TAN Tumour-Associate Neutrofils
TADC Tumour-Associated Dendritic Cells
TAM Tumour-Associated Macrophages
TC-M(p Tumour- Contioned Macrophages
TEM Angiopoietin-2 receptor Tie2
TGF Transforming Growth Factor
TIL Tumour Infiltrating Lymphocyte
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TLR Toll-Like Receptor
TNF-a Tumour Necrosis Factor
TME Tumour Microenvironment
VEGF Vascular Endothelial Growth Factor
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1 INTRODUCTION
1.1 The Immune System
The mammalian immune system is composed of two branches: innate and adaptive 
immunity, which cooperate to protect the host against microbial infections, injury, sterile 
wound healing, and to maintain homeostatic balance of tissues. Innate immunity is 
evolutionarily the oldest mechanism of defence against microbes and is present in many 
species, from primitive multicellular organisms to vertebrates (Hoffmann & Akira, 2013). 
However, during evolution, the development of adaptive immunity allowed the immune 
system of vertebrates to recognize and neutralize more efficiently and rapidly invading 
pathogens.
In adaptive immunity, pathogen-specific receptors are "acquired" during the lifetime of 
the organism, whereas in innate immunity receptors recognizing pathogen-associated 
molecular patterns (PAMPs), such as lipopolysaccharide, peptidoglycan, lipotheichoic 
acids and cell-wall lipoproteins, are already encoded in the germline. Through these 
receptors the adaptive immune response mediates effective and specific attacks against 
microorganisms, in cooperation with the innate immune system (Hoffmann & Akira, 
2013). In the adaptive immune system, the generation of highly diversified receptors is the 
result of somatic recombination of germline-encoded segments, and provides high 
recognition specificity for foreign antigens, immunological memory of infections and 
development of pathogen-specific adaptor proteins; this mechanisms is mediated by 
Histocompatibility Complex (MHC) molecules (Medzhitov, 2007). However, as the 
adaptive immune system is able to mediate the anti-microbial response, it may also be 
responsible for allergy, autoimmunity and the graft versus host disease (Janeway & 
Medzhitov, 2002).
The innate immune system, also known as the non-specific immune system, represents 
a first-line host defence mechanism. It is composed of a cellular and a humoral arm. The
cellular arm comprises primarily leukocytes, such as neutrophils and macrophages that 
mediate the early phase of the innate immune response to the infectious agents crossing the 
structural barriers of the organism (Medzhitov, 2007). On the other hand, the humoral arm 
includes soluble molecules, such as complement components, lectins, pentraxins and 
defensins, produced and released by innate immune cells (Bottazzi et al, 2010 ). When a 
given pathogen invades the host, it is initially recognized by cells of the innate immune 
system. In the case the innate immune system is not successful in removing the pathogen, 
it can activate the adaptive immune system to efficiently eradicate the infection. The 
recognition of pathogens can be also performed by non-immune cells such as epithelial 
cells, fibroblasts, and endothelial cells.
Vertebrates sense microbial invasion by utilizing various pattern recognition receptors 
(PRRs) including Toll-like receptors (TLRs), Nod-like receptors (nucleotide-binding 
oligomerization domain receptors - NLRs), RIG-I-like receptors (intracellular pattern 
recognition receptor - RLRs), and C-type lectin receptors (CLRs) (Hoffmann & Akira, 
2013). These PRRs are located on the cell surface and/or in the cytoplasm. They activate a 
series of events leading to the production by the innate immune cells of several cytokines 
and chemokines (IL-1; IL-6; IL-10; TNF; CCL2), and to the recruitment and accumulation 
of leukocytes and immune cells involved in the inflammatory response (such as 
neutrophils and macrophages). Basically, the inflammatory response is initially promoted 
by dendritic cells expressing microbe-derived peptides associated with the major 
histocompatibility complex (MHC) on the cell surface (Hoffmann & Akira, 2013). 
Dendritic cells migrate from the infected tissues to the regional lymph nodes, where they 
present the antigen to specific T lymphocytes. This results finally in the activation of 
adaptive immunity (Hoffmann & Akira, 2013). Moreover, the innate immune system has 
evolved to be activated by microbes, therefore autoimmunity events that might be caused 
by an improper activation of the adaptive system are unlikely to be the result of the innate 
immunity activation (Medzhitov, 2007). It is remarkable that these innate responses not
only play a key role as first line of defence against pathogens, in the homeostasis and 
maintenance of tissue integrity, but are also involved in the activation and regulation of 
adaptive responses.
1.2 The Immune System and Cancer
It is now accepted that the immune system plays at least three distinct roles in 
preventing cancer: (i) it protects the host against viral infections and hence suppresses 
virus-induced tumours; (ii) it prevents the establishment of an inflammatory environment 
that facilitates tumorigenesis by promoting a prompt resolution of sterile and pathogen- 
induced inflammation; and (iii) it eliminates tumour cells in certain tissues, recognized 
thanks to the expression of ligands for activating receptors on innate immune cells and 
tumour antigens recognized by the adaptive immune system (Schreiber et al, 2011).
1.2.1 Cancer immunosurveillance
Accordingly to the cancer immunosurveillance hypothesis, cells of the immune system 
could be able to recognize and destroy continuously arising transformed cells. This 
hypothesis was tested over the years to determine whether tumour development is 
influenced by an impaired immune system (see for review (Dunn et al, 2002; Schreiber et 
al, 2011). Of particular note were experiments showing that the cancer susceptibility 
(spontaneous or carcinogen-induced tumour) of immunocompetent mice was similar to 
that of nude mice that had major but not total immunodeficiency (Stutman, 1975). 
Following this evidence, the cancer immunosorveillace hypothesis was abandoned and 
have been brought forward other hypotheses according to which tumour cells did not 
possess “danger signal” needed to activate immune system (Matzinger, 1994), or immune 
system would ignore or be tolerant to a progression of tumour because tumour cells are 
very similar to normal cells (Pardoll, 2003). On the other hand, others demonstrated that a 
persistent activation of a pro-inflammatory arm of innate immunity could facilate tumour 
progression promoting tumour proliferation, compromising the protective function of the
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innate system (Balkwill & Mantovani, 2001; Karin et al, 2002). Despite the controversial 
observations, due mainly to the limited models utilized at that time, by the 1990s improved 
mouse model of immunodeficiency allowed to reassess the role of immunity on cancer 
development.
A number of discoveries led to a renewed interest in the idea of cancer 
immunosurveillance. First of all, endogenously produced interferon y (IFN-y) was 
demonstrated to protect the host against the development of tumours, both chemically 
induced and spontaneous (Dighe et al, 1994; Kaplan et al, 1998). Secondly, mice lacking 
perforin (perforin-/-), a cytolytic protein found in the granules of cytotoxic T lymphocytes 
(CTLs) and natural killer (NK) cells, were more prone to develop tumours (van den Broek 
et al, 1996), demonstrating, together with the first observation, that the immune system is 
involved in the control of tumour formation. Moreover, using Recombinant-Activation 
Gene knock-out (RAG-/-) mice, which completely lack natural killer T (NKT), T and B 
cells, it was demonstrated that lymphocytes were not only necessary to protect the host 
against chemically induced sarcomas but also against spontaneous tumours (Shankaran et 
al, 2001; Shinkai et al, 1992). The tumour suppressor mechanisms dependent on IFN-y, 
perforin and lymphocytes are heavily overlapped indicating that both the innate and the 
adaptive arm of the immune system are involved (Dunn et al, 2002; Mittal et al, 2014; 
Schreiber et al, 2011).
On the other side it has been shown that the immune system can lead to the 
immunoselection of tumour cells that are more capable of surviving in an 
immunocompetent host (Dunn et al, 2002; Mittal et al, 2014; Schreiber et al, 2011). Based 
on this, the immune system exerts an apparent paradox that consists of two opposite effects 
on developing tumours: being on one side protective for the host and on the other 
promoting tumour growth. In particular, cancer immunosurveillance is thought to act at the 
earliest stages of cellular transformation, whereas, the tumour editing effect can become
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overwhelming, at late stages. This process, in all its features, could no longer be named 
“immunosurveillance”, and the term “immunoediting” was proposed (Dunn et al, 2002). 
Cancer immunoediting is the result of three processes: elimination, equilibrium and escape, 
a concept known as the “three Es” (Figure 1).
The elimination process corresponds to the original concept of cancer 
immunosurveillance and during this phase the immune system recognizes and tries to 
destroy the transformed cells (Matzinger, 1994). If the elimination of all these cells is 
successful, there is no progression to the next step and the tumour is eradicated without 
any clinical manifestation (Dunn et al, 2002; Mittal et al, 2014; Schreiber et al, 2011; 
Vesely & Schreiber, 2013). In particular, cellular transformation leads to the induction of 
an inflammatory response with recruitment of cells of the innate immune system: NK cells, 
NKT cells and ydT cells recognize structures on the transformed cells and initiate 
production of IFN-y, which in turn can exert an apoptotic and antiproliferative effect on 
tumour cells (Dunn et al, 2002; Matzinger, 1994; Schreiber et al, 2011). Moreover, IFNy 
also induces the secretion in the microenvironment of pro-inflammatory anti-angiogenic 
chemokines, such as CXCL9, CXCL10 and CXCL11, by tumour cells and other host cells. 
Chemokines sustain the recruitment of NK cells and monocytes, which differentiate into 
macrophages. Recruited cells can thus contribute to the elimination of tumour cells. In 
parallel, local dendritic cells engulf tumour cell debris and migrate to draining lymph 
nodes, where they activate CD4+ and CD8+ T cells. Activated T cells migrate to the 
tumour site, where antigen-bearing tumour cells can be recognized and destroyed by 
cytolytic lymphocytes.
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Figure 1: Cancer immunoediting concept. Cancer immonoediting consists of three phases: elimination, 
equilibrium, and escape. In the elimination phase, the immune system recognizes and destroys tumors before 
they become clinically apparent. If  a rare cancer cell variant is not destroyed in the elimination phase, it may 
then enter the equilibrium phase. The constant immune selection pressure, placed on tumor cells genetically 
unstable can promote the appearance of rare cancer cell variants no longer recognized by the immune system. 
Such cells may thus enter the escape phase. During the escape process, the uncontrolled expansion o f the 
surviving tumor variants occurs resulting in the clinical manifestation of the malignant desease. Figure taken 
from Schreiber et al. 2011.
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The equilibrium phase is a dynamic process generated by the activity of the immune 
system itself on the tumour mass (Schreiber et al, 2011). Equilibrium can become the 
longest phase of cancer immunoediting, eventually extending throughout the life of the 
host. During the equilibrium phase, growth of residual tumour cells is kept under control 
by the immune system, maintaining transformed cells in a “dormant state” for a long time, 
until they accumulate a combination of alterations sufficient to allow them to evade 
immune recognition and resume their growth as either recurrent primary tumours or distant 
metastases (Aguirre-Ghiso, 2007). Evidence for the requirement of a functional immune 
system to sustain the equilibrium phase came from primary tumorigenesis experiments 
showing that administration of a low-dose of carcinogen [3methylcholanthrene (3-MCA)] 
to immunocompetent mice did not result in the development of tumours, despite cancer 
cells being maintained for an extended period of time (Koebel et al, 2007). However, 
ablation of the immune system in these mice by administration of monoclonal antibodies 
(mAbs) that deplete T cells and IFN-y, resulted in a rapid tumour outgrowth. Therefore, 
equilibrium is the result of growth inhibition and cytotoxic activity mediated by the 
immune system on the residual tumour cells. Nevertheless, the constant activity and 
suppression of tumour expansion by the immune system, represents a selective pressure 
that pushes tumour cells to acquire immuneevasive mutations, leading to what is defined 
evasion or “escape” (Mittal et al, 2014).
In the escape process, the uncontrolled expansion of the surviving tumour variants
occurs and this results in the clinical manifestation of the malignant disease (Mittal et al,
2014; Schreiber et al, 2011). Tumour cell escape can occur through many different
mechanisms (Dunn et al, 2002; Mittal et al, 2014; Vesely et al, 2011). Alterations leading
to reduced immune recognition or increased resistance to the cytotoxic effects of the
immune system (for example, through induction of anti-apoptotic mechanisms or
expression of anti-apoptotic effector molecules such as BCL-2) promote tumour outgrowth
(Khong & Restifo, 2002; Smyth et al, 2006). Moreover, tumour cells can develop at least
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three different ways to evade immune recognitions: 1) silencing the expression of tumour 
associated antigens, 2) preventing the expression of MHC class I proteins that present 
these antigens to tumour-specific T cells, or 3) hampering the antigen processing 
machinery necessary for the association of tumour antigens with MHC class I molecule. 
All of these alterations might be, at least in part, the result of on-going genomic instability, 
which is a common feature of transformed cells. The final outcome of the selection of 
poorly immunogenic tumour cell variants, no longer sensed by the immune system, 
unleashed to grow indefinitely.
1.2.2 Cancer-related inflammation
Inflammation is a complex immune editing process that normally protects the organism 
from invading pathogens and preserves homeostasis in the presence of tissue damage 
(Medzhitov, 2008). It is now generally accepted that inflammation has a role in 
tumorigenesis (Balkwill & Mantovani, 2012). Chronic inflammation has been shown to 
contribute to tumorigenesis at different stages: i) tumour initiation, by inducing genotoxic 
stress; ii) tumour maintenance, by promoting cell growth and proliferation; iii) tumour 
progression, by enhancing angiogenesis and tissue invasion (Grivennikov et al, 2010). 
Therefore, it has been proposed that inflammation and tumour immunity are mutually 
exclusive (Balkwill & Mantovani, 2012). Epidemiological studies have shown that chronic 
inflammation can increase the risk of cancer leading to the definition of cancer-related 
inflammation (Balkwill & Mantovani, 2012; Mantovani et al, 2008b). However, other 
evidence is available supporting the idea that tumour-promoting inflammation and 
protective tumour immunity might be reciprocally correlated (Bui & Schreiber, 2007). In 
fact, if on one side the immune system is able to “shape” cancer cells during 
immunoediting, the tumour mass can have a strong influence on the immune system itself. 
Thus, inflammation and tumour immunity might be considered a dynamically 
interconnected process in which tumour cells take over through cancer immunoediting.
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This hypothesis is supported by various data: development of chemically induced tumours 
(such as upon treatment with 3-MCA) is dependent on the presence of pro-inflammatory 
cytokines/signalling molecules [e.g. interleukin-ip (IL-ip), IL-23 or MyD88]; once the 
tumour is formed, growth of transformed cells can be controlled by other cytokines (such 
as IFNy, IFNa/p, IL-12) or T cells. Moreover, components of the immune system showing 
pro-oncogenic activity can also induce tumour immunity during the development of 
cancer: MyD88 and IL-ip promote carcinogen induced-tumorigenesis in mouse models 
(Krelin et al, 2007; Swann et al, 2008). In addition, at later stages of tumour development 
the same proteins exert a protective response against tumours, promoting the recognition of 
transformed cells (Balkwill & Mantovani, 2012; Ghiringhelli et al, 2009). Finally, studies 
both in mouse models and Drosophila showed that tumour-necrosis factor (TNF) can have 
both tumour-promoting and anti-tumour activities (Cordero et al, 2010), and that IFNy is 
required both for Ultraviolet B-induced tumour formation and for immune rejection of the 
same tumours (Zaidi et al, 2011). Therefore, inflammation provides an important 
contribution to tumour escape; i.e. when inflammatory cells are recruited to the site of a 
growing tumour, they are activated by the paracrine production of cancer-related 
molecules, such as vascular endothelial growth factor (VEGF), and repress immune 
responses against the tumour itself (Grivennikov et al, 2010).
Tumour initiation, as well as the genetic and epigenetic aberrations leading to 
transformation of normal cells, are dramatically favoured by chronic inflammation 
(Mantovani et al, 2008a). Its pro-tumoral contribution is exerted by establishing a tissue 
microenvironment favourable for tumour growth, and by preventing an effective anti- 
tumoral immune response (Trinchieri, 2012). Accordingly, in the tumour 
microenvironment (TME), inflammatory cells and molecules influence almost every aspect 
of cancer progression and as shown in Figure 2. Based on this, cancer-related inflammation 
has been added as the seventh hallmark of cancer (Colotta et al, 2009).
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Figure 2. Hallmarks of cancer The hallmarks of cancer proposed by Hanahan and Weinberg (2000) 
include: unlimited replicative potential, ability to develop blood vessels (angiogenesis), evasion of 
programmed cell death (apoptosis), self-sufficiency in growth signals, insensitivity to inhibitors of growth, 
and tissue invasion and metastasis. The inflammatory microenvironment has been recently proposed as the 
seventh hallmark of cancer. Taken from Colotta et al, 2009.
1.2.3 Intrinsic and extrinsic pathways in inflammation and cancer
Inflammation and cancer are interlinked in two main ways: intrinsic and extrinsic 
pathways (Figure 3). Inflammation associated with cancer initiation is defined as intrinsic 
when the mechanisms that are involved in cell transformation, typically oncogene over­
expression or mutations, are also responsible for the activation of a pro-inflammatory 
programme (Karin, 2006). On the other hand, extrinsic inflammation is the result of tissue 
response to malignant cells, and is most predominantly mediated by infiltrated 
inflammatory cells. (Mantovani et al, 2008b; Trinchieri, 2012).
Causes of the intrinsic pathway of inflammation are re-arrangements of genes 
implicated in the tyrosine-kinase pathways, mutations in the RAS family proteins and in 
the oncogene MYC (encodes a transcription factor), which are not only necessary and 
sufficient for cancer development, but also directly promote the generation of 
inflammatory conditions (Guerra et al, 2007; Soucek et al, 2007). Uncontrolled 
proliferation and survival of cells, epithelial-to-mesenchymal transition, angiogenesis,
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tumor cell migration and metastasis, altered response to hormones and chemotherapeutic 
agents, are expected to be observed as downstream effects of oncogenic variations 
(Mantovani et al, 2008b). As shown in Figure 3, the early genetic events are able to induce 
the expression of cytokines, chemokines, prostaglandins and thus to instruct the 
remodelling of the microenvironment, which will in turn promote tumour progression, 
invasion and metastasis (Mantovani et al, 2009).
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Figure 3. Pathways that connect inflammation and cancer. Inflammation and cancer are connected by 
two pathways: an intrinsic pathway, driven by oncogenic mutations that cause both inflammation and 
neoplasia, and an extrinsic pathway, driven by inflammatory conditions that favors the tumor development. 
Figure taken from Mantovani et al, 2008
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The interplay between the intrinsic and extrinsic inflammatory pathways can be 
exemplified in the case of pancreatic carcinoma, in which both an extrinsic inflammatory 
condition (pancreatitis) and the mutation in the gene encoding K-RAS (intrinsic pathway) 
are necessary to drive carcinogenesis (Borrello et al, 2005; Guerra et al, 2007). The 
intrinsic pathway is able to promote inflammation through the activation of endogenous 
key transcription factors such as Nuclear Factor kappa-light-chain enhancer activated B 
cells (NF-kB) and Signal Transducer and Activator of Transcription 3 (STAT3) 
(DiDonato et al, 2012; Yu et al, 2007). NF-kB, in particular, has emerged as an important 
tumour promoter. This transcription factor is activated upon engagement of Toll-like 
receptors by microorganisms or damaged tissues (TLR-Myd88 signalling pathway) 
(Mantovani et al, 2008a). It regulates the production of several inflammatory cytokines, 
chemokines, adhesion molecules and angiogenic factors. In addition it activates the 
prostaglandin synthesis pathway and promotes cell survival and growth, inhibiting 
apoptosis and favouring the response to hypoxia (DiDonato et al, 2012). These 
inflammatory conditions promote leukocyte infiltration, which occurs in most tumours. 
Tumour infiltrating leukocytes are mainly myeloid cells and their subpopulations [tumour 
associated macrophages (TAMs), monocytes expressing the angiopoietitn-2 receptor Tie2 
(TEM), myeloid derived suppressor cells (MDSC), tumour associated neutrophils (TAN) 
and tumour-associated dendritic cells (TADC)], mast cells, T cells, NK cells, dendritic 
cells (Balkwill, 2004; Brennecke et al, 2014). Importantly, it has to be considered that 
many cells residing in the inflamed tissue where the tumour originated, including the 
surrounding non-transformed epithelial and stromal cells, are affected by the 
environmental stimuli locally generated (Brennecke et al, 2014). In this environment, 
genetic instability is fostered leading to the selection of mutation(s) responsible for the 
expansion of a single tumour clone. At the same time the normal counterpart will remain
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quiescent or will die because of senescence, or destruction by innate and adaptive immune 
cells, but also an excessive DNA damage could cause cell death.
1.3 The tumour microenvironment
Cancer is a complex “rogue” organ in which malignant cells and host cells coexist, and 
contribute to the formation of the tumour microenvironment (TME). Host cells in the 
tumour microenvironment include fibroblasts, endothelial and immune-competent cells 
(Hanahan & Coussens, 2012). All together tumour and host cells orchestrate molecular and 
cellular events taking place in surrounding tissues (Figure 4).
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Figure 4. The primary tumour microenvironment. TME is characterized by a huge infiltrate of immune 
cells (macrophages, neutrophils, lymphocytes), by new-born blood vessels and deregulated ECM proteins 
Figure taken from Pollard et al., 2009.
Besides host cells, a wide array of biologically active molecules are available in the 
tumour microenvironment in soluble form or associated to component of the extracellular 
matrix (ECM) (Bomstein & Sage, 2002). ECM is an essential component of TME and it is 
composed by fibrous proteins (e.g. collagen, elastin, cheratin) embedded in a gel of 
glycosaminoglycans, proteoglycans and glycoproteins. It not only constitutes the structural 
scaffold for cellular elements of the stroma, but also exerts a direct influence on cell
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growth, differentiation and migration (Schultz et al, 2011). Several ECM molecules, 
defined as “matricellular proteins” by Bomstein and Sage, are able to interact with cell- 
surface receptors and with other microenvironment components. These include cytokines, 
chemokines, growth factors and proteases, that altogether can affect various cell functions. 
Interestingly, the idea that tumour stroma may have an impact on the biological behaviour 
of neoplasms is as old as the first histological observation of a neoplasia (Dhom, 1994).
The extensive remodelling of the tumour ECM compartment is mainly carried out by 
macrophages, a key cell of the TME (Brennecke et al, 2014). They act through two main 
processes: (i) the degradation of pre-existing ECM molecules by a number of hydrolytic 
enzymes (e.g. proteases) produced, activated and /or induced by neoplastic cells and (ii) 
the de novo synthesis of ECM components, which, in many cases, are not present or are 
present at low concentrations in normal tissue. Transforming growth factor p (TGF-P) is a 
potent inducer of ECM proteins such as collagens, tenascin, thrombospondin, osteopontin, 
elastin, the secreted protein acidic and rich in cysteine (SPARC) and fibronectin (Roberts 
et al, 1992). Such modified tumour ECM could generate a more suitable, permissive and 
/or instructive environment for tumour growth and progression (Lu et al, 2012).
The evolution, structure and activities of the cells in the TME have many parallels with 
the processes of wound healing and inflammation (Mantovani et al, 2008b). However cells 
such as macrophages are also found in cancers that have no known association with 
chronic inflammatory conditions (Grivennikov et al, 2010; Hanahan & Coussens, 2012; 
Mantovani et al, 2008b). This because inflammatory and wound-healing processes can be 
also activated downstream of oncogenic mutations in the malignant cells (Mantovani et al, 
2008b).
Inflammation is a consistent feature of the tumour microenvironment, and as described
above has been considered the seventh hallmark of cancer (Balkwill & Mantovani, 2012;
Colotta et al, 2009; Coussens et al, 2013; DiDonato et al, 2012; Mantovani et al, 2008b).
As suggested by recent estimates, 25% of cancers ' are associated with chronic
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inflammation sustained by infections (e.g. hepatitis) or inflammatory conditions of diverse 
origin (e.g. prostatitis) (Balkwill & Mantovani, 2012). In addition, even tumours not 
directly connected to inflammation are characterized by the presence of cells and 
mediators of the inflammatory response (Grivennikov et al, 2010).
1.3.1 Cells of the tumour microenvironment
As mentioned above, host cells, including leukocytes, fibroblast and endothelial cells, 
infiltrate tumours (Brennecke et al, 2014). Leukocytes, and in particular myeloid cells, are 
the most consistent cellular infiltrate of solid tumours. Tumour associated myeloid cells 
(TAMC) mainly support tumour growth and progression, thereby contrasting the T-cell 
infiltrate, which mainly has anti-tumoral activity (Brennecke et al, 2014).
TAMC all arise from hematopoietic stem cells (HSC) within the bone marrow, and 
further differentiate into macrophage/granulocytes progenitors. The myeloid populations 
that infiltrate tumours modulate tumour-mediated immunosuppression, tissue remodelling, 
tumour progression and metastasis (Mantovani & Sica, 2010). Similarly to tissue 
macrophages, TAMC demonstrate high plasticity, resulting in the two extreme Ml and M2 
phenotypes for polarized macrophages and N1 and N2 phenotypes for polarized 
neutrophils (see below) (Mantovani, 2009; Mantovani et al, 2005; Qian & Pollard, 2010). 
Cross-talk between the different cellular components was demonstrated, resulting in tuning 
of the adaptive immune response, promotion of angiogenesis and tissue remodelling 
(Mantovani & Sica, 2010).
Results obtained so far clearly indicate that TAMC are major players in the connection 
between inflammation and cancer. Recent work has led to a better understanding of their 
biological properties, indicating that myeloid cells infiltrating growing tumours could have 
a prognostic value, thus representing an attractive target for novel biological therapies of 
tumours (Fridman et al, 2012).
Although cancer-related inflammation is considered to be tumour-promoting, as
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described above, the immune-surveillance of cancer does exist: inflammatory cells can 
recognize and destroy tumour cells, following the immunoediting theory (Schreiber et al, 
2011). The tumour mass is able to shape the immune system and the balance between 
tumour-promoting (Th2 cells and M2 macrophages) and tumour-destructive (Thl and Ml 
macrophages) immune response is perhaps significant for cancer development (Mantovani 
& Sica, 2010). A key point that needs to be addressed in future studies, is how to trigger a 
"good" immune response during anti-cancer therapy. Tumour associated macrophages 
seem to have a crucial role in the generation of a tumour-promoting microenvironment, 
whereas Ml macrophages are necessary for the elimination of tumour cells and elicit 
cancer-inhibiting immune response (Mantovani et al, 2008b). Re-education of 
macrophages could be a good target to reverse the tumour-supporting activity (M2-like) of 
these cells towards antitumor function (Ml- like).
As already mentioned, tumours are highly infiltrated by different types of immune cells 
that profoundly contribute to the shaping associated of micro-environment (Brennecke et 
al, 2014). Macrophages, dendritic cells, neutrophils, lymphocytes and myeloid-derived 
suppressor cells (MDSC), all seem to play crucial activities within the malignant context, 
as well as fibroblasts, pericytes and sometimes adipocytes.
1.3.1.1 Tumour-associated macrophages (TAMs) 
Tumour-Associated Macrophages (TAMs) belong to the early infiltrating leukocyte
population within tumours, thus preceding lymphocytes, and are usually the most abundant
immune population in the tumour microenvironment, representing up to 50% of the tumour
mass (Mantovani et al, 2008b; Qian & Pollard, 2010). TAMs are fundamental actors in
tumour growth, where their activities are usually pro-tumorigenic.
Monocytes are known to originate in the bone marrow under the influence of
interleukin-la (IL-la), IL-6, IL-13 (Geissmann et al, 2010) and macrophage-colony
stimulating factor (M-CSF or CSF-1), which stimulates their differentiation, as well as
their proliferation and viability in vitro, from a common myeloid progenitor. Various
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molecules produced either by neoplastic and by stromal cells are involved in the 
recruitment of monocytes from the blood to the tumour site. Monocyte the differentiation 
is also influenced by their localization within the tumour mass. For instance, a gradient of 
IL-10 can switch monocyte differentiation towards macrophages rather than dendritic cells 
(Allavena et al, 1998). Thus, as observed in breast cancer and papillary carcinoma of the 
thyroid, TAMs are present throughout the tissue whereas DC are present only in the 
periphery (Scarpino et al, 2000).
Monocytes express the of M-CSF receptor (MCSF-R, CD 115) which is a useful marker 
to define these cells (Chitu & Stanley, 2006). Monocytes also express a wide range of 
scavenger receptors and upon stimulation they release reactive oxygen species (ROS), 
complement factors, prostaglandins, nitric oxide (NO) and cytokines (e.g. TNF, IL-ip, 
CXCL8, IL-6, and IL-10), VEGF and proteolytic enzymes (Auffray et al, 2009). 
Moreover, they express chemokine receptors (e.g. CXCR1) and adhesion receptors 
mediating migration from blood to tissues during inflammatory/infection conditions.
Monocytes are effectors of the immune response to microbial infections, are implicated 
in many inflammatory disease and can be recruited into tumour sites, where they are 
involved in the regulation of tumour development (Peranzoni et al, 2010). Once released 
into the peripheral blood, monocytes circulate for severaLdays before horning to tissues 
and replenishing macrophage populations. Macrophages differentiate into subpopulations 
of tissue macrophages and closely related myeloid dendritic cells (Steinman & Idoyaga, 
2010), the latter specialized to present antigens to naive T helper lymphocytes, 
contributing to host defence, tissue remodelling and repair (Auffray et al, 2009).
In the steady state, in the absence of overt inflammation, resident macrophages populate
organs constitutively and mediate trophic and homeostatic roles, e.g. removing apoptotic
cells and serving as sentinels of injury and infection (Gordon & Martinez, 2010). Once an
early inflammatory response, such as acute infection, has occurred, monocytes rapidly
invade injured tissues and differentiate to macrophages. Tissue macrophages are terminally
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differentiated cells that show a distinct rate of proliferation depending on the stimuli and 
the tissue microenvironment. They are biosynthetically active and can recognize foreign, 
normal or abnormal cells, acting as very efficient scavenging cells.
The chemokine CCL2 (also known as monocyte chemotactic protein 1; MCP-1), 
described in 1983 as a tumour-derived chemotactic factor, is the main player involved in 
macrophage accumulation within tumours (Bottazzi et al, 1983; Negus et al, 1995). Several 
studies have correlated CCL2 levels with TAM abundance in many experimental and 
human tumours such as ovarian, breast and pancreatic cancer (Balkwill, 2004; Bottazzi et 
al, 1983). TAM themselves produce CCL2, suggesting the action of an amplification loop 
(Solinas et al, 2009). Other chemokines involved in monocytes recruitment are CCL5, 
CCL7, CXCL1 and CXCL12, as well as such as urokinase plasminogen activator (uPA), 
TGF-|3, basic fibroblast growth factor (bFGF), VEGF and platelet derived growth factor 
(PDGF), as well as antimicrobial peptide (e.g. human beta-defensin-3) and the growth 
factor M-CSF (Allavena et al, 2008b; Balkwill, 2004). Moreover, monocytes can also be 
attracted by fibronectin 1 (FN1), fibrinogen and other factors produced during the cleavage 
of ECM proteins induced by macrophages and/or tumour cell-derived proteases (Allavena 
et al, 2008a; DeNardo et al, 2008).
Early studies demonstrated that appropriately stimulated macrophages are able to kill 
tumour cells in vitro (Erreni et al, 2011). However TAM, conditioned by the tumour 
microenvironment, lose their cytotoxic capability, and rather exert several pro-tumoral 
functions, mediating cancer-related inflammation, angiogenesis, immune-suppression, 
tissue remodelling and metastasis (see below) (Mantovani et al, 2008b; Pollard, 2004).
1.3.1.2 Dendritic cells
Dendritic cells are heterogeneous professional antigen-presenting cells of bone-marrow
origin that are critical for the initiation of primary T-cell response (Steinman, 1991). There
is evidence that DCs play a key role in the induction of tumour-specific immune responses,
especially via cross-priming which allows the transfer of antigens from tumour cells to
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DCs, their presentation through MHC-class I antigens and the generation of CD8+ cytolytic 
T cells.
In the TME, DCs are defective, that is, they cannot adequately stimulate an immune 
response to tumour-associated antigens (Gabrilovich, 2004). In patients with cancer, it has 
been shown that rapidly growing tumours contain small numbers of DCs and that those 
cells usually have the phenotype of immature DCs (Brennecke et al, 2014). These DCs 
express no or low levels of the co-stimulatory molecules CD80 and CD86; e.g., DCs 
derived from melanoma metastases do not express CD86. Tumours produce 
immunosuppressive factors that block maturation and impair differentiation of DCs. It has 
also been proposed that the high numbers of immature DCs found in tumours is due to 
increased migration. In fact, tumour-derived cytokines and chemoattractant factors 
controlling DCs infiltration (MIP-3a/CCL20) were shown to modulate their recruitment. 
Other data were collected from patients with breast, melanoma, renal cell and prostate 
carcinoma, indicating that various malignancies could actively recruit immature DCs to the 
tumour site and impede their differentiation (Bell et al, 1999).
An hypoxic and inflammatory microenvironment has been found to impair DC 
functions. Several reports have now confirmed that, by releasing IL-10, IL-6, M-CSF, 
VEGF and prostanoids, tumours are able to prevent DCs differentiation, maturation and 
function in vitro and in vivo (Brennecke et al, 2014).
1.3.1.3 Neutrophils
Neutrophils are short-lived white blood cells derived from bone marrow myeloid
precursors and attention has long been focused on their short-term antimicrobial and 
tissue-damaging function (Cassatella, 2006). Cytokines, including those involved in 
tumour progression such as IL-ip, dramatically prolong their survival and reprogram their 
function. Moreover, polymorphonuclear leukocytes (PMN) are themselves a conspicuous 
source of inflammatory cytokines (Mantovani et al, 2011).
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Elevated levels of tumour-associated neutrophils (TANs) were observed in biopsies 
from patients with colon adenocarcinoma compared with the surrounding non-tumoral 
tissue (Tazzyman et al, 2009). In these biopsies, neutrophils were found throughout the 
tumour but their numbers increased further in invasive and ulcerated areas. Increased 
numbers of neutrophils have also been observed in patients with myxofibrosarcoma, 
gastric carcinoma and melanoma (Mantovani et al, 2011).
Mirroring the Ml and M2 classification proposed for macrophages, neutrophils have 
been recently divided into N1 and N2 cells (Mantovani et al, 2011). N1 neutrophils exert 
anti-tumorigenic activities that include the expression of more immunoactivating cytokines 
and chemokines, low levels of Arginase 1 (Argl), will the capability of killing tumour 
cells in vitro. On the other hands, the N2 polarization driven by TGF-|3 has been associated 
with a protumorigenic phenotype (Fridlender et al, 2009).
In untreated malignancies, TAN have been reported to support neoplastic growth by 
producing angiogenic factors and matrix-degrading enzymes (Galdiero et al, 2013), by 
supporting the acquisition of a metastatic phenotype and by suppressing the antitumor 
immune response (Schmielau & Finn, 2001). These observations are consistent with the 
hypothesis that most TANs appear to have an N2 phenotype and thus contribute to tumour 
growth and immunosuppression. Depleting these protumorigenic N2 neutrophils would 
thus be expected to inhibit or reduce tumour growth, as shown by several studies 
(Fridlender et al, 2009; Nozawa et al, 2006).
In particular, Fridlender has reported that in lung cancer and mesothelioma models, 
CD8+ T cell activation results in increased recruitment of N1 neutrophils with anti-tumour 
activity (Fridlender et al, 2009). Conversely, depletion of N2 polarized neutrophils results 
in retardation of tumour growth.
Preliminary data has suggested that at least part of the source of neutrophil-attracting 
chemokines is from tumour-associated macrophages, indicating a strong interaction
between these two tumour infiltrating immune populations (Mantovani, 2009).
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1.3.1.4 Lymphocytes
More than 100 years ago, malignant tumours were first noted to contain variable
numbers of lymphocytes (Balkwill & Mantovani, 2012), which are known as tumour 
infiltrating lymphocytes (TILs). Initially, these TILs were thought to reflect the origin of 
cancer at site of chronic inflammation (Balkwill & Mantovani, 2001) and later it was 
debated whether TILs provided a favourable environment for cancer growth or rather 
reflect the host’s attempt to eliminate cancer (Rollins, 2006). A high percentage of tumour- 
infiltrating lymphocytes is usually associated with better prognosis (e.g. for melanoma, 
colorectal and ovarian cancer) (Clemente et al, 1996; Curiel et al, 2004; Pages et al, 2005) 
even though in gastric cancer a high number of TIL seems to correlate with tumour 
progression (Xie et al, 2008) and in head and neck squamous cell carcinomas (HNSCCs) 
the role of TILs is still controversial (Uppaluri et al, 2008).
Distinct T cell populations characterize the tumour microenvironment at the invasive 
tumour margin and in draining lymphoid organs. Among these, CD8+ T cells supported by 
CD4+ T helper 1 (Thl cells), which are characterized by the production of IL-2 and IFN-y, 
correlate with a good prognosis (Fridman et al, 2012). Contrary to this, other CD4+ T cells, 
such as Th2 cells producing IL-4, IL-5 and IL-13, which support B cell responses, or Thl7 
cells, producing IL-17A, IL-17F, IL-21 and IL-22 that favour antimicrobial tissue 
inflammation, are generally thought to promote tumour growth (Fridman et al, 2012). 
However they have also been associated with a favourable outcome, as in the case of Th2 
cells in breast cancer (Yoon et al, 2010) and Thl7 cells in esophageal cancer (Lv et al, 
2011).
Over the last few years a number of reports have described elevated numbers of 
regulatory T (FOXP3+ and CD25+) (Treg) cells inside or in close proximity to tumours, 
draining lymph nodes and also in peripheral blood of cancer patients (Beyer & Schultze,
2009). There is increasing evidence that Treg cells can migrate into tumours and suppress 
effective anti-tumour responses in the tumour-microenvironment through the production of
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IL-10 and TGF-|3 and through cell-mediated contact with cytotoxic T-lymphocyte antigen 
4 (CTLA4), thus contributing to the growth of human tumours (Campbell & Koch, 2011).
In addition, several mechanisms have been described to explain the conversion of 
conventional CD4 (+) T cells into Treg cells in the context of human tumours (Beyer & 
Schultze, 2009). Yet little is known about the molecular and cellular features responsible 
for the increase and maintenance of elevated levels of Treg cells in cancer (Beyer & 
Schultze, 2009). Thus, targeting Treg cells provides an attractive therapeutic strategy to 
potentially influence the suppressed immune response in tumour patients, thereby altering 
and supporting anti-tumour therapy.
1.3.1.5 Myeloid-Derived Suppressor Cells (MDSC)
Myeloid-derived suppressor cells are a heterogeneous population of immature myeloid
cell, that have the ability to suppress T cells functions (Brennecke et al, 2014; Gabrilovich 
et al, 2012). They derive from myeloid progenitors in bone marrow that have not 
differentiated into mature granulocytes, macrophages or dendritic cells. MDSC have been 
isolated from blood, spleen and bone-marrow of tumour-bearing mice. In addition MDSC 
infiltrate the tumour tissue, where local tumour-associated factors promote their activation. 
In tumour-bearing mice, two main subset of MDSC were identified: monocytic MDSC (M- 
MDSC), characterized by CDllb+, Ly6G', Ly6Chigh, and granulocytic MDSC (G-MDSC), 
characterized by CDllb+, Ly6Ghigh, Ly6C\ M-MDSC and G-MDSC show different 
functional activities: M-MDSC mediated immune suppression is based on the up- 
regulation of inducible nitric oxide synthase (iNOS), expression of Argl and production of 
suppressive cytokines, whereas G-MDSC mediated immune suppression is characterized 
by antigen-specific responses (including ROS release requiring prolonged MDSC and T 
cell contacts) (Gabrilovich et al, 2012). Moreover M-MDSC possess the ability of 
differentiating into monocytes (macrophages) and dendritic cells, whereas G-MDSC do not 
possess this potential (Youn et al, 2008).
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Tumour-associated MDSC generally exhibit a M2-like phenotype, while Ml and M2 
phenotypes could coexist in some mouse models (Brennecke et al, 2014). Human MDSC 
have been isolated from blood of patients with glioblastoma, colon cancer, breast cancer, 
lung or kidney cancer, and are still poorly characterized (Dumitru et al, 2012). Recent 
studies have proposed that human MDSC have a characteristic CD34+, CD33+, CDllb+, 
and HLA-DR- profile. Similarly to the murine counterpart, human MDSC are divided into 
two main subset: monocytic MDSC (M-MDSC), characterized by the expression of CD 14, 
and granulocytic MDSC (G-MDSC), identified by positivity for CD 15 (Gabrilovich et al, 
2012).
1.4 Macrophages and Cancer
As outlined above, TAMs are the most abundant host cell population infiltrating 
tumours and are indicators of the strong inflammation present at the tumour sites (Balkwill 
& Mantovani, 2012; Coussens et al, 2013; DeNardo et al, 2008; DiDonato et al, 2012). 
Myeloid cells exposed to the tumour microenvironment most frequently promote tumour 
progression. TAM were shown to promote tumour growth directly through the production 
of trophic and activating factors by stromal and cancer cells such as epidermal growth 
factor (EGF), bFGF, VEGF, PDGFp, and TGF-p (Mantovani et al, 2008b). For example, 
IL-13 and IL-4 produced by CD4+ T cells infiltrating tumours, led to the production and 
secretion of EGF by TAM (Aspord et al, 2007). In addition TAMs can promote 
angiogenesis and resistance to therapies. Plasticity and diversity are hallmarks of myelo- 
monocytic cells and the regulatory pathways involved in such plasticity can orchestrate the 
yin-yang interactions between TAM and tumour cells.
1.4.1 Macrophage plasticity
In general, macrophages can be identified by a combination of different markers 
expressed on their surface, such as CD68, CD14, CD16, CDllb and CD163 (Cook & 
Hagemann, 2013). Indeed, they are able to acquire different polarization states, in response
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to environmental cues, such as microbial products, damaged cells and activated 
lymphocytes (Biswas & Mantovani, 2010).
Classical (M l) or alternative (M2) polarization represent the two extremes of a 
continuum of functional states, which occur in vivo either under physiological conditions, 
such as ontogenesis and pregnancy, or in pathology, such as allergic and chronic 
inflammation, tissue repair, infection and cancer (Sica & Mantovani, 2012) (Figure 5).
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Figure 5. Macrophage plasticity in human pathologies. M l and M2 polarization as the two extremes of a 
continuum of functional states. Dynamic changes in the functional state are observed in human pathologies. 
For example, a switch from M l to M2 macrophage polarization characterizes the transition from early to 
chronic phases of infections. Taken from Sica and Mantovani,(2012).
Mirroring the Thl/Th2 paradigm, classical activation, which generates M l macrophages, 
occurs in the presence of bacterial compounds (i.e. LPS) and Thl typical cytokines, such 
as IFNy (Martinez et al, 2008). On the other hand, the alternative M2 activation is 
dependent on Th2 typical cytokines, such as IL-4 and 1L-13. M l macrophages, defined as 
IL-12hl, IL-23hl, IL-10low, are characterized by the production of effector molecules 
(reactive oxygen and nitrogen intermediates), Thl and NK attracting chemokines (CXCL9,
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CXCL10), and pro-inflammatory cytokines (IL-1|3, TNF, IL-6), which in turn promote the 
Thl response, exerting a strong microbicidal and tumoricidal activity (Sica et al, 2008). 
However, M2 cells defined as IL-12low, IL-10hl, IL-ldecoyRhl, IL-lRAhl, are considered to 
be involved in parasite containment and clearance and promotion of tissue remodelling 
together with Th2 cells. They express CCL17, CCL22 and CCL24, have 
immunoregulatory functions and promote tumour development and progression (Allavena 
et al, 2008a; Gordon & Martinez, 2010; Martinez et al, 2006 ; Sica & Mantovani, 2012).
Ml and M2 macrophages are distinct cells that exert opposite functions and respond to 
different stimuli (Mantovani et al, 2004). Analysing the gene expression profile of Ml and 
M2 macrophages showed that more than 1200 genes are selectively regulated. (Martinez et 
al, 2006) For example, molecules implicated in pathogen-recognition, in phagocytosis and 
co-stimulation are typical of Ml macrophages, conferring them with the capability to 
recognize pathogens through pattern recognition receptor, such as TLR (Biswas & 
Mantovani, 2010; Gordon & Martinez, 2010). Contrary to this, M2 macrophages express 
high levels of scavenger receptors and low levels of TLRs (Peiser & Gordon, 2001). 
Indeed, M2 macrophages are involved in the elimination of damaged self-components, 
which are recognized by the scavenger receptors and then eliminated through 
phagocytosis. Although phagocytosis is a key mechanism shared by both classically and 
alternatively activated macrophages, it leads to cytotoxicity and killing of the pathogen in 
Ml macrophages, whereas it favours repair, healing, regeneration and angiogenesis by M2 
macrophages (Gordon & Martinez, 2010).
Ml and M2 macrophages have distinct features in terms of the metabolism of iron, 
folate and glucose (Zhu et al, 2015). Indeed, Ml stimuli are responsible for a shift towards 
the anaerobic glycolytic pathway. This effect mirrors the functional role of Ml 
macrophages, which are associated with acute inflammation and need to quickly exert their 
anti-microbial activity within the hypoxic tissue microenvironment. Anaerobic glycolysis
is the process that best suits their rapid energy requirements (Biswas & Mantovani, 2012).
32
On the other hand, M2 macrophage-related functions, such as tissue remodelling, repair 
and healing, require a sustained supply of energy. Therefore, the metabolic pathway of M2 
macrophages is preferentially based on fatty acid oxidation.
In addition, Ml macrophages express high levels of NOS2 and NO, which exert a key 
role for their microbicidal activity (MacMicking et al, 1997). In contrast, M2 macrophages 
do not produce NO, but express high levels of Arginase 1, which catalyses polyamines 
production necessary for collagen synthesis, cell proliferation, fibrosis and other tissue 
remodelling-related functions (Biswas & Mantovani, 2012).
Macrophage polarization is strictly regulated by a network of signalling molecules, 
transcription factors, epigenetic mechanisms and post-transcriptional regulators. IFNs and 
TLR signalling activate STAT1, whereas IL-4/IL-13 activate STAT6, skewing 
macrophage function towards the Ml or M2 phenotype, respectively (Sica & Bronte,
2007). IRF5 induction, which is downstream the TLR4 pathway activated by LPS, is 
responsible for the expression of cytokines (IL-12, IL-23, TNF) involved in sustaining Thl 
and Thl7 responses (Krausgruber et al, 2011). However, STAT6 activation induces M2- 
related genes, such as mannose receptor (MRC1), while activation of STAT3 induces a 
“M2-like” phenotype (see below), characterized by expression of genes such as IL-10, 
TGF-P, MRC1 (Gordon & Martinez, 2010; Mantovani & Sica, 2010; Pauleau et al, 2004).
NF-kB activation, dependent on TLR engagement, leads to the production of 
inflammatory mediators associated with Ml-macrophages, but is also necessary for the 
resolution of inflammation and for M2 polarization of TAMs (Hagemann et al, 2008; 
Lawrence & Gilroy, 2007). Peroxisome proliferator-activated receptor gamma (PPARy) 
agonists have been shown to induce M2-like differentiation (Bouhlel et al, 2007) and SHIP 
[SH2 (Src homology 2)-containing inositol phosphatase-1] was found to play a key role in 
balancing macrophage polarization, although recent evidence suggests that it may act 
indirectly through the regulation of IL-4 production by basophils (Kuroda et al, 2009).
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Macrophage polarization could be influenced by M-CSF, the key regulator of monocyte 
differentiating processes (Solinas et al, 2009). M-CSF driven monocyte-to-macrophage 
differentiation is associated with a dramatic change in the transcriptome, whereas further 
stimulation with an M2 stimulus (IL-4) caused a smaller alteration in gene expression 
(Martinez et al, 2006). This apparently minor effect of IL-4 is due to the fact that treatment 
with M-CSF elicits functional responses which share some properties with M2 and are 
referred to as M2-like (Allavena et al, 2008a; Mantovani et al, 2005). “M2-like” 
macrophages are induced also by IL-10, TGF-p, glucocorticoid hormones, molecules that 
originate from apoptotic cells and immune complexes together with LPS or IL-1R ligands 
(Allavena et al, 2008a). They are defined as M2-like because they share some M2 features, 
such as the expression of high levels of mannose receptors and scavenger receptors but are 
distinct from them, for instance, in terms of the chemokine repertoire (Biswas & 
Mantovani, 2010).
Mononuclear phagocytes are highly plastic and flexible cells and Ml and M2 
macrophages can, to some extent, be interconverted in vitro and in vivo (Biswas & 
Mantovani, 2010; Guiducci et al, 2005). Moreover, dynamic changes in macrophage 
activation occur in pathology: Ml macrophages are involved in the early and acute phases 
of inflammation, whereas M2 or M2-like macrophages are associated with resolution or 
smouldering chronic inflammation. At the present time, the mechanisms regulating these 
switches are still unclear. In particular, it remains to be defined whether the M l-M2 switch 
is due to recruitment of circulating precursors which polarized into the opposite way, or to 
the in situ re-education of cells (Martinez et al, 2009). The loss of equilibrium between Ml 
and M2 cell number may lead to pathological events: an Ml excess could induce chronic 
inflammatory diseases whereas an uncontrolled number of M2 could promote severe 
immune suppression (Allavena et al, 2008a).
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1.4.2 TAMs as major effector of cancer-related inflammation
Macrophage infiltration, studied in mouse models of tumour carcinogenesis, begins 
very early during the pre-invasive stage of disease and increases progressively. TAM have 
mostly an M2-like polarization (IL-10hi, IL-12low, expression of mannose receptor and SR- 
A), as also indicated by transcriptional profiling (Biswas et al, 2006; Biswas & Mantovani, 
2010; Sakai et al, 2008). In addition TAMs exert several M2-associated functions 
favouring cancer progression, invasion and metastasis, and suppressing anti-tumour 
immunity (Allavena et al, 2008a; Pollard, 2004; Talmadge et al, 2007). In agreement, low 
macrophage infiltration into the tumour mass correlates with the inhibition of tumour 
growth and metastasis development in different animal models (Hiraoka et al, 2008; Lin et 
al, 2006; Zeisberger et al, 2006).
The preferential M2 polarization is due to the absence of Ml orienting signals such as 
IFNy or bacterial components in the tumour as well as to the expression of M2 polarizing 
factors. In particular, the infiltration of Th2 lymphocytes (driven by Th2-recruiting 
chemokines like eotaxin) has been reported in many tumours and they are a fundamental 
source of IL-4 and IL-13 cytokines (Solinas et al, 2009). In addition, neoplastic cells, 
fibroblasts and Treg produce TGF-p and IL-10. Moreover, gene modified mice and cell 
transfer experiments have confirmed the protumor function of myeloid cells and of their 
effector molecules. It has been demonstrated that when MMTV-PyMT mice, which 
spontaneously develop mammary tumours, were crossed with mice lacking 
monocytes/macrophages (op/op), the tumour growth and spread were significantly reduced 
(Lin et al, 2001). Accordingly, when co-cultured with tumour cells, macrophages secrete 
substances, like those that stimulate tumour cell proliferation (Allavena et al, 2008a; 
Balkwill, 2004; Pollard, 2004).
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1.4.2.1 Regulation o f  transcriptional programs in TAMs
HIF-1 and NF-kB were found to be key regulators of the transcriptional program of
TAMs (Mantovani et al, 2006). The reason why NF-kB activation in TAMs is related to
tumour promotion is not completely clear (Lawrence, 2011). TAMs display defective NF-
kB activation in response to various pro-inflammatory signals and this results in impaired
macrophage-dependent inflammatory functions, such as the expression of cytotoxic
mediators (i.e. NO) and cytokines (TNF, EL-1, IL-12p40). This defect was attributed to the
over-expression of the nuclear p50 subunit of NF-kB, which leads to the generation of
homodimers p50-p50, inhibiting NF-kB-dependent genes (Porta et al, 2009). TAMs from
p56-deficient mice re-gained a pro-inflammatory (Ml) phenotype, suggesting that a proper
NF-kB activation is responsible for a “canonical” activation of macrophages (Biswas et al,
2006; Lawrence, 2011). In contrast, it was also shown that blocking NF-kB activation in
TAMs isolated from early-stage tumours increased their tumour-suppressing activity
(Hagemann et al, 2008). These studies suggest that NF-kB favours the M2-like phenotype
in tumour associated macrophages.
The discrepancy concerning the role of NF-kB in TAMs may be explained by the
dynamic changes occurring in the tumour microenvironment during the progression from
early neoplasia towards advanced tumour stages. NF-kB activity in the inflammatory
infiltrate may be progressively modulated by tumour cells themselves, producing several
factors involved in NF-kB regulation (Allavena et al, 2008a; Sica & Mantovani, 2012).
Hypoxic stress is a common feature of solid tumours and it is principally regulated by
the Hypoxia inducible transcription factor (HIF-1), whose activation in cancer cells
favours their survival in a hostile environment (Allavena et al, 2008b). Indeed, it mediates
the switch from aerobic to anaerobic metabolism, resulting in chronic acidification of the
local microenvironment, leading to invasion and metastasis (Semenza, 2003; Vaupel,
2004). In addition hypoxic stress promotes angiogenesis, inhibition of apoptosis, up-
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regulation of growth factors, such as PDGF, TGF-p, IGF-2, EGF, VEGF, and proteins 
involved in tumour invasion (Vaupel, 2004), Finally, it also contributes to cancer cell 
detachment, since it is responsible for down regulation of adhesion molecules and is able 
to influence the position and function of cancer and stromal cells, including TAMs by up- 
regulating the chemokine receptor CXCR4 (Salcedo et al, 1999). TAMs are therefore 
recruited into hypoxic sites and are able to adapt to hypoxia through the activation of 
hypoxia inducible transcription factors HIF-1 and HIF-2, which induce the expression of 
pro-angiogenic genes as well as glycolytic enzymes (Talks et al, 2000).
1.4.2.2 TAMs and angiogenesis
Initiation of angiogenesis in an important early event in tumour progression (Ruoslahti,
2002). Indeed, tumours cannot grow beyond a certain size without recruitment of 
endothelial cells that generate new vessels to supply nutrients and oxygen for tumour cell 
survival. Compared with the vasculature in normal tissues, the tumour vessels differ both 
in morphology and functionality. They are tortuous and leaky; their diameter is irregular 
and their walls are thin. Blood flow through the tumour capillaries is frequently sluggish, 
and at times, might be stationary or even experience a reversal in the direction of flow 
(Tozer et al, 2005).
VEGF is the primary, but not the only, angiogenic factor released by tumour cells, and 
is involved in the “angiogenic switch” that can occur at various stages of tumour 
progression, depending on the tumour type and the microenvironment. Many other factors 
are involved, including PDGFp, bFGF, angiopoietins and CXCL12 (SDF-1) (Du et al,
2008). TAMs have a profound influence on the regulation of tumour angiogenesis, 
expressing various pro-angiogenic molecules, such as VEGF, bFGF, TNFa, IL-113, and 
various chemokines and proteases (Murdoch et al, 2008). Pre-clinical studies demonstrated 
that TAMs positively correlated with microvascular density (MVD) (Leek et al, 1996; 
Takanami et al, 1999), while depletion of monocytes by clodronate treatment results in 
lower TAM infiltration and angiogenesis (Murdoch et al, 2008).
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As mentioned before, hypoxia activates in these cells a specific pro-angiogenic program 
(Mantovani et al, 2002). Low oxygen conditions promote HIF-1 and HIF-2 expression 
with subsequent over-expression of pro-angiogenic molecules. Hypoxia exerts a crucial 
role in the up-regulation of gene transcription in TAMs, promoting VEGF expression 
(Burke et al, 2003; Murdoch et al, 2005). Of note, TAMs express VEGF almost 
exclusively in avascular and perinecrotic areas, as observed for instance in human breast 
carcinomas (Murdoch et al, 2008). The importance of HIF-1 was underlined by the 
observation that in hypoxic regions, the ablation of this transcription factor leads to an 
impaired motility and cytoxicity of macrophages (Cramer et al, 2003). Among 
chemokines, hypoxia tightly regulates the expression of CXCL12, a HIF-1-dependent and 
potent chemoattractant for endothelial cells, and of its receptor CXCR4. In addition to 
CXCL12, TAMs release other chemokines involved in the angiogenic processes such as 
CCL2, CXCL8, CXCL1, CXL13 and CCL5 (Balkwill, 2004; Murdoch et al, 2008). For 
instance, levels of CXCL5 and CXCL8 were associated with increased neo-vascularization 
and inversely correlated with survival (Balkwill, 2004; Mantovani et al, 2004; Strieter et 
al, 2004).
TAMs play also a role in peritumoral lymphoangiogensis, an initial step for the 
spreading of tumour cells. The process is mediated by a number of factors including 
VEGF-C, VEGF-D and their receptor VEGFR3 (Ji, 2012; Schoppmann et al, 2002), all 
secreted or expressed by TAMs (Ji, 2012; Schoppmann et al, 2002). In addition, it has been 
shown that VEGF-A increases lymphangiogenesis via recruitment of monocytes.
1.4.2.3 TAMs and cancer cell dissemination
The major cause of death in cancer results from therapy resistant metastases (Fidler,
t l i1999). Stephen Paget’s conclusion in the late 19 century (Paget, 1989) that the metastatic 
process depends on cross-talk between selected cancer cells (the “seed) and a specific 
organ microenvironment (the “soil”) is still valid, and is experimentally confirmed (Fidler, 
2003; Talmadge & Fidler, 2010). Tumour metastasis is a complex multistep process,
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during which malignant cells spread from the primary tumour site to secondary distant 
organs. The different steps of cancer cell dissemination can be subdivided into local 
invasion, entry into the bloodstream (intravasation), survival in the bloodstream, 
extravasation and colonization (Nguyen et al, 2009).
Mesenchymal, endothelial and immune cells are required to form an appropriate 
microenvironment for tumour progression (Joyce & Pollard, 2009). Immune cells, 
particularly macrophages, neutrophils, T-lymphocytes, and NK cells, are major sources of 
proteases that degrade the host tissue, allowing cancer cells to disseminate. The set of 
proteolytic enzymes found in tumour microenvironment comprises matrix 
metalloproteases, serine proteases and cysteine proteases (i.e.cathepsin) (Decock et al, 
2011; Egeblad & Werb, 2002; Lynch & Matrisian, 2002). Matrix proteases play essential 
functions in physiological conditions as active regulators of post-natal tissue development 
and remodelling (Alford & Hankenson, 2006). In addition, they are important for tissue 
repair in response to injury, and regulate cancer progression modulating the tumour 
microenvironment, particularly the infiltration of leukocytes (Page-McCaw et al, 2007).
TAMs contribute to cancer cell dissemination by releasing several motility factors and 
enzymes involved in degradation of the ECM such as matrix metalloproteinase 2 (MMP2) 
and MMP9, urokinase plasminogen activator, tissue-type plasminogen activator, and 
cathepsin (Gocheva et al, 2010). One of the main factors significantly involved is TNF: co- 
colture of neoplastic cells with macrophages enhances invasiveness of malignant cells 
through TNF-dependent MMP induction in macrophages (Hagemann et al, 2004).
Giavazzi and colleagues demonstrated the IL-lp cytokine produced by TAMs, induces 
a higher development of metastases in a mouse melanoma model (Giavazzi et al, 1990). In 
addition, in a genetic model of breast cancer in monocyte-deficient mice, tumours 
developed normally but, in the absence of the macrophage-produced EGF, they were 
unable to form pulmonary metastases (Pollard, 2008).
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TAMs are important players of tumour progression and metastatic colonization through 
the cross-talk with tumour cells (Brennecke et al, 2014). For instance, macrophages play a 
crucial role in conferring an invasive phenotype to epidermal keratinocytes from Snail 
transgenic mice (Du et al, 2010).
Cytokines produced by TAMs can also play a role in metastatization. In breast cancer, 
EGF secreted by TAMs increases migration and invasion of neighbouring breast cancer 
cells, which express high levels of EGF receptor (EGFR). On the other hand, cancer cells 
secrete high levels of M-CSF, a main chemoattractant for TAMs which expresses the 
cognate receptor MCSF-R. Therapies aiming at inhibiting this cross-talk by blocking 
MCSF-R or/and EGFR were shown to be successful (Goswami et al, 2005). Macrophages 
and their cross-talk with tumour cells are mandatory for tumour cell migration, regardless 
of the factors inducing cell invasion (e.g. CXCL12) (Brennecke et al, 2014).
1.4.2.4 TAMs and immune suppression 
Besides the effect on tumour growth and dissemination, TAMs have also the potential to
suppress the adaptive immune response through different mechanisms including poor
antigen-presenting activity and inhibition of T cell proliferation, leading to cancer immune
evasion (Dunn et al, 2004). As mentioned above, M2-like TAMs are characterized by an
immunosuppressive phenotype, with production of high levels of IL-10 and TGF-P and
reduced expressions of immune-stimulatory molecules such as IL-12 (Biswas et al, 2006;
Biswas & Mantovani, 2010; Hagemann et al, 2008). It has been shown that IL-10, alone or
in concert with IL-6, is responsible for the up-regulation of macrophage B7-H4 expression,
a molecule implicated in the suppression of tumour-associated antigen-specific T cell
immunity (Kryczek et al, 2006).
In this regard, TAMs are also able to influence the adaptive immune response, 
suppressing the potential anti-tumoral activity of B and T cells (Solinas et al, 2009). In 
addition, dendritic cells in the tumour microenvironment were observed to be immature 
and therefore not able to efficiently prime T cells that become anergic. DC maturation is
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blocked because of the secretion of various cytokines by several tumour-associated cells, 
including TAMs, which express high levels of IL-10.
Furthermore, TAMs secreted chemokines such as CCL17 or CCL22, that preferentially 
attract Thl, Th2 and Treg lymphocytes with defective cytotoxic functions, or such as 
CCL18, induced in normal macrophages by Th2 cytokines (IL-4; IL-13; IL-10), that 
recruit naive T cells which become anergic in contact with M2 macrophages and immature 
dendritic cells (iDC) (Banchereau & Palucka, 2005; Mantovani & Sica, 2010). CCL18 has 
been also identified as the most abundant chemokine in the ascites fluid of human ovarian 
carcinoma (Schutyser et al, 2002).
1.4.2.5 TAMs and anti-cancer therapies 
As we discussed above tumour-associated macrophages favour neoplastic cells during
tumour development, invasion and spread to distant sites (Solinas et al, 2009). Therefore
these cells may certainly be considered as an attractive target for novel anti-cancer
therapies. Thus, it is important to ask the question that “if we block macrophages, will we
actually disturb tumour progression in patients?”
As a matter of fact high levels of TAM infiltration generally correlates with poor
outcome for patients (Bingle et al, 2002; Mantovani et al, 2008b; Pollard, 2004; Qian &
Pollard, 2010), but a few exceptions to this finding are also reported. For instance in
colorectal cancer (CRC) there are contrasting results such that TAM density is associated
with positive or negative outcomes (Erreni et al, 2011; Forssell et al, 2007; Ohno et al,
2003). Macrophage subsets might have distinct roles, as observed in lung adenocarcinoma,
where the number of CD204+ TAMs showed a strong association with poor patient
outcome, while the CD68+ TAMs population did not (Ohtaki et al, 2010).
The concept that not only the number and the presence of specific cell subsets, but also
the localization of infiltrating cells might have specific functions and predictive values is
increasingly emerging (Brennecke et al, 2014). Accordingly, peritumoral density of TAMs
expressing co-stimulatory molecules (CD80 and CD86) was associated with better patient
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survival in CRC, whereas the same cell population within the tumours themselves did not 
have predictive value (Sugita et al, 2002). Thus TAMs exert complex roles on growing 
tumours affecting different aspects of tumour progression, namely tumour cell proliferation 
and survival, angiogenesis, tumour dissemination and resistance to therapies.
Within a tumour, the heterogeneous microenvironment differentially influences 
infiltrated macrophages and this clearly shows the necessity of identifying the correct 
TAMs on target for the generation of new therapeutic molecules (Solinas et al, 2009). 
Obviously, the best target would be a protein expressed or over-expressed only by TAMs 
and neither by resident macrophages of distant healthy tissues nor by Ml cells, which are 
important to remove pathogens, and could take part in anti-cancer actions.
Interestingly, observations come from studies performed with chemokines and 
chemokine receptors as anti-cancer targets. For instance, in a breast cancer murine model, 
malignant cells recruit macrophages via CCL5 and treatment with CCL5 receptor 
antagonists leads to a decreased number of infiltrating macrophages associated with a 
significantly reduced tumour size (Robinson et al, 2003).
Recruitment of monocytes into the tumour microenvironment is dependent on CCL2 
and growth factors, such as M-CSF and VEGF, which are also responsible for M2/M2-like 
skewing of macrophages. Inhibition of MCSF-R has an anti-angiogenic and anti-metastatic 
effect in acute myeloid leukemia and melanoma models (Qian et al, 2011).
The anti-tumoural drug Trabectidin (Yondelis) derived from mourine tunicates has 
immunomodulatory properties on mononuclear phagocytes. Our group has recently 
demonstrated that this drug show a selective cytotoxic effect on monocytes and 
macrophages, including TAMs, while sparing the lymphoid subset (Germano et al, 2013); 
moreover, at subcytotoxic concentrations, Trabectidin significantly reduced the production 
of CCL2 (Allavena et al, 2005). CCL2 has also been identified as a fundamental regulator 
of prostate cancer growth and metastasis and its inhibition with anti-CCL2 antibodies, in
combination with docetaxel, induces a significant tumour regression (Loberg et al, 2007).
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Inhibitors of the CCL2/CCR2 axis have also been shown to exert a significant anti-tumoral 
activity in a model of pancreatic cancer (Sanford et al, 2013)
Thalidomide, linomide, pentoxifyline and genistein and other anti-angiogenic factors 
have been demonstrated to inhibit macrophage recruitment and to reduce tumour size 
(Vukanovic & Isaacs, 1995). Moreover, it has been shown that anti-VEGF-A neutralizing 
antibodies reduce the development of new blood and lymphatic vessels and decreased 
incidence of lymphatic and pulmonary metastasis in an orthotopic breast tumour model 
(Whitehurst et al, 2007). As already mentioned, VEGF also promotes macrophage 
recruitment into tumours and Dineen and colleagues demonstrated that specific inhibition 
of VEGFR2 significantly decreases macrophage infiltration into orthotopic pancreatic 
tumours (Dineen et al, 2008).
Other efficient anticancer molecules are MMP inhibitors such as the bisphosphonate 
zoledronic acid (Giraudo et al, 2004). In murine models of genetic carcinogenesis, 
suppression of MMP-9 secretion by TAM results in a slower tumour growth (Melani et al,
2007).
Given that macrophages spontaneously infiltrate tumours, recent studies used these cells 
as natural vectors to deliver therapeutic molecules to the neoplastic site. Intratumoral 
injection of macrophages transduced with a recombinant adenoviral vector expressing IL- 
12 led to the reduction of primary tumour growth and lung metastases in a preclinical 
model of metastatic prostate cancer, with an higher number of tumour infiltrated CD4+ and 
CD8+ T cells compared with the controls animals (Satoh et al, 2003). Another fascinating 
approach is targeting stromal-cancer cell interactions with siRNA (Aharinejad et al, 2009). 
Macrophages were also used to enhance the immune response or to potentiate 
chemotherapy specificity. Carta and colleagues engineered a murine macrophage cell line 
which strongly augmented the production of IFNy (Carta et al, 2001).
A contribution of the immune system to the anti-tumour effects of conventional
chemotherapy has been suggested (Zitvogel et al, 2008). Dying cells can secrete proteins,
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termed DAMPs (damage-associated molecular patterns) that activate innate immune cells 
(Green et al, 2009; Zitvogel et al, 2008). For example, late apoptotic cells express SIN3A- 
associated protein 130 (SAP 130), a ribonucleoprotein which binds to the macrophage- 
inducible C-type lectin receptors (MINCLE). In addition it has been shown that inhibition 
of MINCLE interrupts the release of pro-inflammatory cytokines by macrophages and also 
blocks neutrophil recruitment (Green et al, 2009; Yamasaki et al, 2008).
1.4.2.6 Macrophage reprogramming
The so-called macrophage re-education, which is based on the idea of plasticity of
macrophages, is the “holy grail” of macrophage targeting in cancer treatment (Mantovani 
& Sica, 2010; Sica & Mantovani, 2012). Indeed, polarized macrophages are able to revert 
or at least modify their polarization upon treatment, both in vivo and in vitro. In a large 
clinical study of ovarian cancer, IFN-y was found to induce a phenotype switch in TAMs, 
leading to the activation of tumoricidal properties of these cells (Allavena et al, 1990). In a 
model of pancreatic ductal adenocarcinoma, CD40 agonist antibodies promoted the 
repolarization of TAMs, which started to express high levels of Ml related proteins (MHC 
class II and CD68) and therefore to have an anti-tumoral effect (Beatty et al, 2011). Thus, 
even if therapeutic macrophage targeting has only recently started to be considered as an 
effective approach, it seems to be promising and the identification of mechanisms and 
molecules associated with macrophage plasticity and polarized activation provides a basis 
for macrophage-centered diagnostic and therapeutic strategies.
The balance between Ml and M2 polarized macrophages is a fundamental aspect in 
anti-cancer treatment. Activation of TLR stimulates Ml-polarized macrophages, inducing 
activation of a pro-inflammatory program (Krieg, 2006). Synthetic CpG 
oligodeoxynucleotides (CpG-ODN), detected by TLR9, demonstrated anti-tumour effects 
in many pre-clinical models even though they do not seem to work with large established 
tumours (Krieg, 2004). Moreover, when CpG-ODN have been added to chemotherapy 
agents, both the response and the survival were significantly increased (Manegold et al,
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2008). Rauh and colleagues highlighted the importance of the already mentioned SHIP1 in 
reverting Ml versus M2 polarized macrophages. SHIP1 deficient mice showed skewed 
development towards M2 macrophages (Rauh et al, 2004) and thus pharmacological 
modulators of this phosphatase are under investigations (Guiducci et al, 2005).
Hagemann T. et al. (2008) have shown that the immunosuppressive phenotype in TAMs 
is dependent on the type of activation of NF-kB, which is modulated by malignant 
epithelial cells (Hagemann et al, 2008). Targeting IKK [3 activity in TAMs isolated from 
tumours resulted in NF-kB inactivation, leading to the conversion from a pro-tumour to an 
anti-tumour activity, typical of Ml macrophages. Indeed, the production of IL-10, TNF 
and expression of Arg-1 were reduced, whereas the production of IL-12 and nitric oxide 
synthase were increased. Moreover, TAMs showed enhanced MHC class II expression 
and, when transferred into ovarian cancer bearing mice, they promoted NK cell 
recruitment at the tumour site and a significant decrease in tumour burden.
IFN-y treatment was used to switch immunosuppressive TAMs into Ml-like cells. Upon 
treatment with IFN-y, TAMs expressed high levels of IL-12 and CD68 and low levels of 
IL-10 and IL-T3, enhancing the proliferation of CD4+ T cells and the cytotoxic properties 
of CD8+ T cells. Moreover, they secreted reduced levels of mediators promoting 
suppressive T cell recruitment (CCL-18) and favouring tumour growth and invasion 
(VEGF, MMP9). In addition, it was demonstrated in vitro that, in the presence of ovarian 
ascites, IFN-y skewed monocyte differentiation from TAM-like cells to Ml macrophages 
(Duluc et al, 2009).
From what has been described so far, it is apparent that the tumour microenvironment 
affects profoundly the behaviour of host infiltrating cells. To address the role of the tumour 
microenvironment on the shaping of TAMs, human monocytes from peripheral blood were 
differentiated to macrophages in the presence of tumour-conditioned growth medium (TC- 
MO) and then submitted to global gene profiling (Solinas et al, 2010). The results
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identified a series of up-regulated genes in TC-MO compared to resting monocytes (Figure 
6) (Solinas et al, 2010). Interestingly the global gene profiling comparison of TC-MO, Ml 
and M2 macrophages and TAM revealed that some of the up-regulated genes in TC-MO 
were similarly expressed and regulated in M2 macrophages and TAM, but not in Ml 
polarized macrophages. These results further support the hypothesis that cancer cells can 
induce the M2-like polarization observed in TAM. In particular, among the genes 
differentially up-regulated in TAM and M2 polarized macrophages is FN1.
FN1 is a soluble glycoprotein that mediates a wide variety of cellular interactions with 
the extracellular matrix and plays important roles in cell adhesion, migration, growth and 
differentiation (Mosher & Furcht, 1981)
1.4.2.7 Fibronectin 1 and its onco foetal isoforms
It is known that in transformed cells and in malignancies, the splicing pattern of
Fibronectin pre-mRNA becomes alterated (Kaczmarek et al, 1994), leading to an increased 
expression of oncofoetal isoforms (Oyama et al, 1989; Oyama et al, 1990) which are 
usually highly present both in fetal and human tumour tissues but seldom in the normal 
counterpart. Oncofetal proteins such as Corion Embryonic antigen CEA, a-fetoprotein, 
glypican-3, and nucleophosmin seem to be of embryonic origin, (Lee et al, 2008) and it 
has been widely observed that they are shared between the processes of embryogenesis and 
the one of tumorigenesis (Hendrix et al, 2007). Aggressive tumour cells and embryonic 
progenitors overlap in terms of some properties and thus it might be that also tumour- 
infiltrating stromal cells acquire foetal characteristics when activated by neoplastic signals 
(Hendrix et al, 2007).
Among the several isoforms of FN1 described, the expression of some of them was 
analysed in TC-MO, namely the Extra Domain-A (ED-A) and ED-B and Migration 
Stimulating Factor (MSF).
ED-A and ED-B (Gutman & Komblihtt, 1987; Schwarzbauer et al, 1987; Zardi et al, 
1987) are the most well-known oncofetal isoforms of fibronectin. They are highly
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expressed in many tumours and seem to promote cell spreading and angiogenesis 
(Kaczmarek et al, 1994; Labat-Robert, 2002; Midulla et al, 2000). In particular, ED-B is 
produced during active tissue remodelling, such as in wound healing and in tumour 
angiogenesis processes, giving rise to a prominent perivascular expression pattern 
(Ffrench-Constant et al, 1989). This accumulation around neovascular structures has been 
extensively demonstrated in studies on many different tumor types, in particular, on 
invasive ductal carcinoma (Kaczmarek et al, 1994) and brain tumours (Castellani et al, 
2002), as well as in ocular angiogenesis (Birchler et al, 1999). In addition, Mhawech et al. 
showed that head and neck tumours with a positive staining for ED-B had a trend to a 
significant lower overall survival of patients (Mhawech et al, 2005).
A third oncofoetal FN isoform has been cloned in 2003 by Schor and colleagues and it 
is known as Migration Stimulating Factor (MSF). MSF differ from the other two 
oncofoetal full length isoforms since it is identical to their 70-kDa N-terminus but 
terminates in a unique 10 amino acid long sequence. As described, in TC-MO, MSF is 
more express than ED-A and ED-B isoforms and so we focused our attention on the study 
of this “truncated isoform” and its involvement in tumour microenvironment.
1.5 Migration stimulating factor (MSF)
MSF, which is the focus of this thesis, is a truncated isoform of human fibronectin 1, 
expressed during foetal life (Schor et al, 2003). Ex vivo studies have shown that both MSF 
messenger RNA and protein are expressed by fibroblasts, keratinocytes, and vascular 
endothelial cells in foetal skin, but not by the majority of these cells in the healthy adult 
skin (Schor, 1994; Schor et al, 2003). In addition, Schor and colleagues a
Iso demonstrated that MSF could be constitutively expressed in vitro by foetal fibroblast 
and fibroblast from cancer patients, by tumour cells (carcinoma, melanomas, and gliomas) 
and by tumour-associated stromal cells, but not by healthy adult cells (Schor et al, 1988a; 
Schor et al, 1988b). Recently Solinas et al. found that M2 polarized macrophages, but not
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Ml macrophages, exposed to the TME express MSF (Solinas et al, 2010). This observation 
suggests that MSF may be a good candidate marker of M2-like TAMs.
Family Symbol Devenpoon Fold Increase
C-type lectin R MRCJ Mannose receptor/CD 206 44
CB209 DC-SIGN 3.6
CD302 DCL-I 3
CLEC10A MGL/CD301 2.5
Fey receptors FCGR2B CD32 10
FCGRT Fc for IgG transporter 4
FCGR1A CB64 2,5
Scavenging receptors MSR1 Scavenger receptor, SR-A 9
STAB/ Stabil in f /SPARC-R 6
CD163 GDI 63 5
SCARB1 Scavenger R, class B 3
ECM molecules GPNMB OA 83
SPP1 OPN 26
F13A1 Factor XIII A l II
FN2 Fibronectin 7
Adhesion molecules and related PMP22 Myelin-associated protein 22
SIGLEC1 Sialoadhesin 1 12
SLAMFS €3>2 family member 11
JTGB5 p5 integrin 3.5
cost CDS! 3
SIGIEC7 Sialoadhesin 7 2.7
SELPLG P selectin ligand 2.5
ITGA4 a4 subunit, VLA4 2.1
Enzymes ADAMDEC1 Decysin 7
CPM Carboxipepfidase 6
MMP9 MMP9 6
ADAM28 ADAM28 4
PLAV uPA 4
MMP2 MMP2 3
MHC molecules and related HLA-DMA HLA-DMA 5
am MHC IL, tramactivator 3
CTSC Gathepsln C 9
CTSD Cathcpsin D 4
CTSR Cathepsin B 3
CTSK Cathcpsin K 2.01
Protein trafficking VPS45 Vacuolar sorting protein 5
VPS13B Vacuolar sorting protein 3.01
LAMP1 Lysosomal protein 1 3
IAMP2 Lysosomal protein 2 3
Miscellaneous SEPPI Selenoprotein 1 95
Human monocytes were stimulated for 72 h with tumor*€M. Results (mean of three different donors) are fold-istetesse 
relative to unsumutated monocytes.
Figure 6. Gene expression analysis o f TC-MO. Genes upregulated in TC-MO compared to resting 
monocytes. Transcriptional profile has been analysed after 72 hrs o f culture. Taken from Solinas et al. (2010)
1.5.1 MSF structure and functions
Human MSF is a soluble, genetically truncated isoform of human FN1 (EMBL
AJ2535086) (Schor et al, 2003). The expression of MSF protein is controlled at the post-
transcriptional level by a two-step mechanism. The primary 5.9 Kb MSF transcript is
generated from the fibronectin gene by read-through mechanisms between exons III-la and
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Ill-lb  followed by intra-intronic cleavage. The 5.9 kb MSF pre-messenger has an AU-rich 
instability element in its 3’-UTR that promotes rapid degradation of the transcript when 
sequestered in the nucleus. In cells expressing MSF protein the pre-messenger RNA is 
further cleaved to produce a 2.1 kb mature mRNA that is rapidly transported to the 
cytoplasm for translation (Kay et al, 2005).
The mature mRNA has a 1,941 bp long sequence identical to the 5’ coding sequence of 
FN1 up to exon Ill-Ia. In addition it contains a 195 bp long intron-derived 3’-sequence, 
immediately contiguous with exon III-la and containing a 30 bp in-frame sequence coding 
for the MSF-unique 10-amino acids long peptide (VSIPPRNLGY). Finally there is a 165 
bp 3’-UTR containing five in-frame stop codons and terminating with a poly (A) tail (Kay 
et al, 2005). MSF protein is 657 amino acid long and has a predicted molecular weight of 
70 kDa. Thus the primary amino acidic sequence of MSF is identical to the N-terminal 
region of FN 1 up to and including the amino-acid sequence encoded by exon III-1 a, with 
the addition of the MSF-unique 10-amino acid long peptide VSIPPRNLGY (Kay et al,
2005) (Figure 7).
Hep1/Fib1
F M — , ,
Fib2Cell-BD
III I)i HI
• Hep1/Fib1
M S F - I-1- F I - 1 Unique decam er
IGD motifs
Figure 7. Comparison of the domain structure of MSF and FN1. MSF protein is identical to the N- 
terminal region of FN1 and terminates with a 10-amino acid long sequence (VSIPPRNLGY) not present in 
any previously identified fibronectin isoform. The black arrows show the IGD motifs that affecs fibroblast 
and endothelial cell migration. Figure adapted from Schor AM and Schor SL, (2010).
Both developmental and physiological signals, such as TGF-|3, control the transcription 
and translation of MSF mRNA (Borsi et al, 1990; Keski-Oja et al, 1988; Wrana et al, 
1991). Kay showed that TGF-p increases 3’-UTR processing of the nuclear 5.9 kb MSF
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mRNA. However, at the same time, it promotes the synthesis of 5.9 kb MSF mRNAs, 
leading to the preferential increase of cytoplasmic levels of 2.1 kb MSF mRNA after TGF- 
j3 treatment (Kay et al, 2005).
Truncated fibronectin isoforms have also been detected in cDNA libraries from goldfish 
and rainbow trout, as well as from mouse and human liver, prostate, ovary, brain and 
spleen (Liu et al, 2003). Unpublished results mentioned by Schor & Schor (Schor & Schor, 
2010) report the existence of a murine MSF protein expressed during foetal development, 
and a similar generation of MSF mRNA has been observed in Zebrafish embryo (Zhao et 
al, 2001).
MSF is a potent motogenic protein, involved in the stimulation of the migration of 
epithelial cells (normal and tumoural), adult-derived skin fibroblasts, vascular endothelial 
cells and pericytes (Houard et al, 2005; Hu et al, 2009). These cells show a typical bell- 
shape dose response with half-maximal activity at 0.1-1.0 pg/ml, corresponding to 
femtomolar concentrations.
MSF also induces the migration of non-epithelial tumour cells and shows other 
activities that characterize tumour progression, such as the up-regulation of hyaluronan 
(HA) synthesis, proteolysis, and induction of angiogenesis (Ellis et al, 1992; Houard et al, 
2005; Hu et al, 2009; Schor & Schor, 2010; Schor et al, 2003; Schor et al, 1989).
The IGD tripeptide motif (isoleucine-glycine-aspartic acid) is a highly conserved
feature of fibronectin type I modules to which no biological functionality was initially
ascribed (Hynes, 1986). MSF contains four such IGD motifs (Figure 7). In vitro
mutagenesis studies have indicated that the stimulation of fibroblast migration by MSF is
mediated by two IGD motifs present in type I modules 1-7 and 1-9, whereas all four IGD
motifs (1-3; 1-5; 1-7; 1-9) affect endothelial cell migration (Ellis et al, 2010). Critically,
small IGD-containing synthetic peptides mimic all MSF bioactivities, such as the
stimulation of cell migration, endothelial cell activation and angiogenesis (Schor & Schor,
2010). IGD motifs are cryptic in fibronectin, for this reason FN1 does not show the
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peculiar activities displayed by MSF (Millard et al, 2007; Vakonakis et al, 2009). MSF 
also maintains the proteinase activity exerted by FN1, dependent on the presence of the 
putative zinc-binding site HEEGH located in type I module 1-8 (Unger & Tschesche, 1999) 
(Houard et al, 2005). Interestingly the proteinase activity exerted by MSF seems to mediate 
the motogenic response of a breast cancer cell line (MCF7) (Houard et al, 2005).
MSF induces endothelial cell activation in vitro, with appearance of a network of cells 
characterized by a sprouting phenotype (Schor et al, 2001; Schor et al, 1983). In addition 
MSF induces angiogenesis in rats and pigs implanted with collagenous matrices soaked 
with MSF (Schor & Schor, 2010).
1.5.2 Regulation of MSF expression
The ECM plays an important role on regulation of MSF expression. Schor et al 
demonstrated that normal adult fibroblasts, normally not producing MSF, can be induced 
to express the protein by a transient treatment with TGF-P, but only when they are growing 
on a “wounded” substratum in vitro (such as a denatured type I collagen or fibrin). This 
expression is persistent for the entire subsequent lifespan of the treated fibroblasts, even if 
cultured in the absence of TGF-p and irrespective of the nature of the substratum. 
Moreover, as a consequence of a second transient exposure to TGF-p, MSF expression 
may be switched off, provided that the cells are growing on a “healthy” matrix of native 
type I collagen. Thus, this “on/off’ switch is repeatable and dependent on the concerted 
action of TGF-p and the presence of an appropriate matrix (Schor et al, 2012).
Epigenetic studies demonstrate a persistent switch-on of MSF expression following a 
transient exposure of normal adult fibroblast to 5’-azacytidine, a pharmacological agent 
inducing changes in gene expression through CpG island demethylation (Schor & Schor,
2010). Consistent to what is described above, this induced expression may be switched-off 
by a subsequent exposure of activated cells to TGF-p when grown on a native collagen 
substratum. These observations indicate that the nature of the substratum is a critical
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component in the regulation of MSF expression. Thus the effects of TGF-p on target cells 
are dependent on the nature of the ECM. This is true also in the case of fibroblast 
migration, that is manifested by cells adherent to native, but not denatured type I collagen 
substratum. Native collagen may accordingly be considered to provide a “permissive” 
substratum, whereas denatured collagen is “non-permissive” (Schor & Schor, 2010; Schor 
et al, 1999; Schor et al, 2003).
Besides TGF-P, MSF bioactivities can be modulated by various soluble factors, 
including neutrophil gelatinase-associated lipocalin (NGAL), produced by “resting” 
keratinocytes (Ellis et al, 1992; Jones et al, 2007). In addition neutralizing anti-MSF 
antibodies were described that can induce apoptotic death of target endothelial cells (Schor 
et al, 2003). This suggest that MSF could also act as an autocrine survival factor.
Finally, there is evidence that MSF can be expressed during tumour formation in human 
cancer-associated myofibroblasts (Carito et al, 2012). This work indicate that 
overexpression of MSF is sufficient to confer myofibroblastic differentiation by increased 
TGF-p signalling. In addition, MSF activates NF-kB, resulting in the onset of 
autophagy/mitophagy, thereby driving glycolytic metabolism (L-lactate production) in the 
tumour microenvironment (Carito et al, 2012). Thus, MSF can participate in the metabolic 
remodelling of the tumour microenvironment by reprogramming cancer-associated 
fibroblasts toward a glycolytic metabolism.
The potential clinical relevance of these findings is highlighted by the observation that 
constitutive MSF expression by foetal and cancer patient fibroblasts may be persistently 
switched off by the exposure to TGF-P of cells growing on a native collagen substratum 
(Schor et al, 2012). The possibility to down regulate the potentially deleterious MSF 
expression by pharmacological intervention suggests that it may be possible to develop 
novel therapeutic strategies blocking MSF expression in particular clinical contexts.
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1.5.3 MSF as a novel target for clinical intervention
A systematic assessment of MSF expression in human tumours is still lacking, however 
the data available so far indicate that more than 80% of common human tumours are 
characterized by MSF expression (Schor & Schor, 2010). Recent data showed that high 
MSF expression in tumours and tumour-associated stromal cells correlates with a poor 
survival in patients with breast cancer and salivary gland tumour (Schor & Schor, 2010). 
These observations suggested that MSF could represent a new marker associated with 
neoplastic transformation. Thus, assessment of MSF expression could provide independent 
prognostic information. Using an unbiased proteomic screening, MSF has been identified 
as a critical angiogenic factor driving oesophageal cancer progression (Hu et al, 2009). 
This evidence supports the role of MSF in cancer pathogenesis. Yoshino et al (2007) have 
additionally reported that MSF expression is induced also by the exposure of a 
bronchioloalveolar carcinoma cell line to the tobacco carcinogen benzo[a]pyrene (Yoshino 
et al, 2007).
As mentioned, tumour-conditioned culture medium was able to induce MSF expression 
in TC-MO (Solinas et al, 2010). TC-MO display a gene expression profile that resembles 
M2 polarized macrophages and TAMs (Solinas et al, 2010). These observations suggest 
that MSF could be a novel molecule associated with the M2 and M2-like polarization and 
for this reason could represent a new marker for identification of TAMs in human tumours 
(Solinas et al, 2010).
The various facets of MSF expression and bioactivity outlined above suggest that MSF 
may be considered as a novel target for clinical intervention. Such intervention strategies 
may involve agents that modulate its reversible expression (including siRNA therapy) 
and/or abrogate manifestation of its bioactivities (neutralizing antibodies and/or 
pharmacological agents). The clear influence of microenvironmental parameters in 
modulating both its expression and manifestation of its bioactivities offer additional 
potential means of clinical manipulation.
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2 AIM OF THE STUDY
Migration Stimulating Factor is an oncofetal isoform of human fibronectin 1 known for 
long time, but only recently its production has been found selectively up-regulated in M2 
and M2-like polarized macrophages (Solinas et al, 2010).
Tumour-associated macrophages are major components of the host cell infiltrate of 
tumours and are characterized by a M2-like phenotype (Mantovani & Allavena, 2015). 
Strong epidemiological and experimental evidences have demonstrated that TAMs 
profoundly affect the tumour milieu expressing several pro-tumoural functions (e.g. 
tumour proliferation and invasion, angiogenesis, ECM degradation) and eventually 
promoting tumour progression and resistance to therapy (Solinas et al, 2009). Importantly, 
high levels of TAM are associated with bad prognosis in many tumours (Solinas et al,
2009).
These findings suggest that MSF could be a potential marker for tumour progression 
associated to M2-like polarization of tumour infiltrating macrophages and a promising 
target for anti-cancer therapy. Thus aim of this project was:
a) to generate reagents (recombinant protein and antibodies) useful to identify MSF in 
human tumours and in tumour-bearing subjects.
b) to characterize the biological properties of human MSF.
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3 MATERIALS AND METHODS
3.1 Reagents
The list of primers used to amplify MSF mRNA by PCR is reported in Table 1. Two sets 
of primers were used: CL1 amplified a 771 bp fragment in the 5’end of both MSF and 
FN1, while CL2 produced a 1448 bp fragment specific for the 3’ end of MSF. The 
sequence of forward and reverse primers for Real-time quantitative PCR (RT-PCR) is also 
reported in Table 1.
Table 1. se MSF expression in TC~ MO
Set of
Restriction site and Primers (5*—»-3*) bpa)
Tmb)
(C°)
CLl
Fw 5’- (BamHI)CGGGATCCCGCAAACTTGGTGGCAACTTGCCT-3’ 771
68
Rev 5 ’-GTCCTGATCGTTGCATCT-3 ’ 48
Fw 5 ’ -G AG A AGCCCT ACC A AGGCTGG AT G ATGGT AG ATT GT ACTT G- 3’ 69
CL2
Rev 5 ’ - (N otl) AT A AG AATGCGGCCGCT A ATT GTT GGCTG A A A AGCTGGGAA-3
1448
68
RT- Fw 5 ’-GCATTGCCAACCTTTACAGAC-3 ’ 177 60qPCR Rev 5, t t t c t g g g t g g g a t a c t c a c -3’
a) Amplicon size
b) Melting temperature
Human Fibronectin 1 (FN1) was purchased from Calbiochem (Merck, Milan, Italy); 
rabbit polyclonal antiserum anti-FNl (ab299) was purchased from Abeam (Cambridge, 
UK); mouse anti-FNl antibody (MAB 1892) recognizing the gelatin-binding domain of 
fibronectin (Gel-BD; clone 1ST-10) was purchased from Millipore (Merck, Milan, Italy). 
Mouse mAb recognizing histidine tail was obtained from Invitrogen (Milan, Italy). Fetal 
calf serum (FCS) was from Euroclone (Milan, Italy); RPMI-1640 and Dulbecco Modified 
Eagle's Medium (DMEM) from LONZA (Euroclone, Milan, Italy). Phosphate buffered 
saline (PBS) with calcium and magnesium (PBS+/+) was from Biosera (Biotecna, Milan,
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Italy), while PBS without calcium and magnesium (PBS7") was from LONZA (Euroclone), 
as well as trypsin used for cell culture; geneticin (G418) was from Sigma-Aldrich (Milan, 
Italy).
The synthetic peptide specific for human MSF used for immunization was synthetized 
by PRIMM S.r.l. (Milan, Italy). A Cystein was added at the COOH-terminal to the ten 
amino acids long peptide (VSIPPRNLGY). The peptide was conjugated to Keyhole limpet 
hemocyanin (KLH) (VSIPPRNLGYC-KLH).
A 105 amino acids long fragment of human MSF (His-MSF; from residue 553 to 657 in 
the C-terminal portion of MSF, in red in Figure 8) including the specific MSF decapeptide 
at the C-terminus (in blue in Figure 8) and a histidine tag at the N-terminus (in black in 
Figure 8) has been produced in bacteria and purified by PRIMM. The recombinant 
fragment has a predicted molecular weight of 14.335 kDa.
10 20 30 40 50 60
MGSDKIHHHH HHHHHHGVWR CDPVDQCQDS ETGTFYQIGD SWEKYVHGVR YQCYCYGRGI
70 80 90 100 110 120
G2WHCQPLQT YPSSSGPVEV FITETPSQPN SHPIQWNAPQ PSHISKYILR WRPVSIPPRN
123
LGY
Figure 8. Sequence of His-MSF produced by PRIMM. The sequence of His-MSF expressed comprises the 
last 105 amino acids of human MSF (from residue 553 to residue 657, in red) and a 18 amino acid long tail 
containing 10 histidine (in black) at the NH2 terminus. The specific MSF peptide is indicated in blue and 
underlined.
3.2 Cell lines
CHO (Chinese hamster ovary), Hela (Human Cervical Cancer), A549 (Human 
Adenocarcinomic Alveolar Basal Epithelial cells), HEK293T (Human Embryonic 
Kindney), and MDA-MB231 (Human Breast Cancer) cells were cultured in Dulbecco 
Modified Eagle's Medium (DMEM) with 10% (v/v) Foetal calf serum (FCS). HCT 116, 
SW620, SW480, RKO, HT29 (Human Colon Carcinoma), 8387 (Human Fibrosarcoma), 
PANC1 and PT25 (Human Pancreatic Cancer) cell lines were cultured in RPMI with 10% 
FCS.
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SP2/0 myeloma cells used for the generation of hybridomas were grown in DMEM with 
10% FCS.
3.3 Animals
CDl nude mice, CB17/SCID and C57B1/6J mice were obtained from Charles River 
(Charles River Laboratories, Calco, Italy). Procedures involving animals and their care 
were conformed to institutional guidelines in compliance with national (4D.L. N.116, 
G.U., suppl. 40, 18-2-1992) and international law and policies (EEC Council Directive 
86/609, OJ L 358,1,12-12-1987; NIH Guide for the Care and Use of Laboratory Animals, 
US National Research Council 1996). The procedures used in the present study were 
approved by the Animal Care and Use Committee of the Istituto Clinico Humanitas and by 
Ministero della Salute (authorization No 09/2013-B).
Animals were housed in the specific pathogen free Animal Facilities at Istituto Clinico 
Humanitas. Groups of 5-7 mice were housed in individually ventilated cages with 12 hours 
dark/light cycle and ad libitum access to autoclaved food and water. A certified 
veterinarian was responsible for animal welfare supervision and regular health monitoring 
of the animal facilities. All efforts were made to minimize the number of animals used and 
their suffering. Animals were euthanized by cervical dislocation after sedation.
3.4 Gel electrophoresis and Western blot analysis
Polyacrylamide gels (10% w/v) were run in the discontinuous buffer system of Laemmli 
(Laemmli, 1970). Samples were diluted in 0.5M Tris-HCl pH6.8, 0.1% (v/v) Sodium 
Dodecyl Sulphate (SDS), 1% (v/v) Bromophenol blu, 3% (v/v) Glycerol, 10% (v/v) |3- 
mercaptoethanol (sample buffer). Gels were stained with Silver Staining Kit (Sigma- 
Aldrich) following the manufacturer’s instructions. For western blot analysis, proteins 
were transferred (lhour at 100 Volt) to nitrocellulose membrane (pore size 0.45[im, 
Biorad) using lx Transfer Buffer TG [25 mM Tris, 192 mM Glycine pH 8.3, 20 % (v/v)
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Methanol; Bio-rad]. To verify protein transfer after blotting, the membranes were stained 
with Ponceau S staining solution (Sigma-Aldrich). Membranes were then briefly washed 
with water and blocked for 1 h. at RT in blocking solution [5% (w/v) milk in PBS+/+ 
containing 0.1% (v/v) Tween 20]. After blocking, filters were incubated overnight at 4°C 
with primary antibodies (RAB1 and RAB2 5pg/ml; mouse mAb a-His 3pg/ml) diluted in 
blocking solution. After three washes with washing buffer (PBS+/+, 0.1% Tween 20), 
membranes were incubated with the appropriate anti-rabbit or anti mouse IgG-horseradish 
peroxidase conjugate, and finally developed with ECL (Enhanced Chemiluminescence, 
Immobilon Western, Millipore) according to the manufacturer’s instructions. Precision 
Plus Protein Dual Color Standards (Bio-Rad, Milan, Italy) were used to determine the 
molecular weight of the proteins.
3.5 Protein evaluation
Total protein content was routinely evaluated by Bradford assay (Thermo Scientific, 
Milan, Italy). The concentrations of homogeneous preparations of recombinant MSF (i.e., 
as assessed by analytical SEC, SDS-PAGE and immunoblotting analyses) was determined 
by UV absorbance at 280 nm using a value of 150000 M'1 cm'1 for the protein's extinction 
coefficient [i.e., as computed by the ProtParam algorithm from the primary sequence of 
MSF (Gasteiger et al, 2003)].
3.6 Real-time PCR
Basal MSF gene expression was measured in different human cancer cell lines by Real 
Time-quantitative PCR (RT-qPCR) (Giulietti et al, 2001).Total RNA was extracted with 
PUREzol RNA Isolation Reagent (Biorad, Milan, Italy) as described above from MDA- 
MB-231, PANC1, HCT116, RKO, HT29, SW480, SV620, Hela, A549, A293T, 8387 
cancer cell lines.
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Forty ng of cDNA, 500 nM of forward and reverse primers (sequence are reported in 
Table 1) and 10 pi of SYBR MIX FAST (Applied Biosystem) in a final volume of 20 pi 
per reaction in 96-well format were used. Accumulation of fluorescent products was 
monitored using a 7900HT Fast Real-Time PCR System (Applied Biosystem). Specificity 
of PCR reaction was controlled by the melting temperature profiles of final products 
(dissociation curve). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene was used 
as control housekeeping gene for normalization. Transcript fold enrichment was calculated 
by A Act method (Livak & Schmittgen, 2001).
3.7 ELISA
3.7.1 Indirect ELISA
ELISA was used to analyse the specificity of polyclonal and monoclonal antibodies 
developed in this study. To this aim either the MSF specific peptide (VSIPPRNLGYC- 
KLH or recombinant His-MSF (section 3.1) were immobilized on plastic wells. In addition 
indirect ELISA was routinely used to detect human MSF in culture supernatant of 
transfected cells.
In general, ELISA plates (Nunc Maxisorb immunoplates) were coated (O/N at 4°C) 
with His-MSF (500 ng — 1 pg/well), the purified peptide (1 qg/well), human fibronectin 1 
(1 qg/well), or supernatant from transfected clones diluted in 15 mM Na carbonate buffer 
(pH9.6). Non-specific interactions were blocked by incubation for 2 h at room temperature 
with 5% (w/v) dry milk in PBS+/+ and 0.05% Tween 20 (washing buffer). Wells were 
washed three times with washing buffer, then 10-1 pg/ml of anti-MSF polyclonal antisera 
diluted in washing buffer were added and incubated 1 h at room temperature. Anti-rabbit 
IgG labelled with horse-radish peroxidase (GE Healthcare) were then added (1/2000 in 
washing buffer) and incubated 1 h at room temperature. Reaction was developed with 
3,3',5,5'-tetramethylbenzidine (TMB; Thermo Scientific, Milan, Italy) and stopped with
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2N H2S04 before reading absorbance at 450 nm with an automated plate reader (Versamax 
microplate reader). Each sample was analysed in triplicate and results are reported as mean 
OD450 ± SD or SEM, as indicated in figure legends. Baseline was obtained adding anti- 
MSF antibody on PBS-coated wells.
3.7.2 Sandwich ELISA
To evaluate the amount of recombinant MSF produced by transfected cells we set up a 
sandwich ELISA. To this aim we tested different antibodies recognizing the N-terminal 
portion of FN1 conserved in human MSF as well as polyclonal antibodies and the 
monoclonal antibody MoAb_E10, recognizing MSF and developed in the present study 
(see sections 3.10 and 3.11). Acceptable results were obtained using the monoclonal 
antibody MAB 1892, recognizing the Gel-BD domain of human FN1, as capturing 
antibody, while the polyclonal antibody RAB1.2 was used to specifically detect bound 
MSF. A standard curve was generated using a purified preparation of recombinant MSF 
(Lot # 3) previously quantified by UV absorbance. ELISA plates were coated (O/N at 4°C) 
with MAB 1892 at a concentration of lug/ml in 15 mM Na carbonate buffer (pH9.6). Non­
specific interactions were blocked by incubation for 2 h at room temperature with 5% dry 
milk in washing buffer. After washing, different amounts of MSF diluted in washing buffer 
were added (0.01-2.5 pg/ml) and incubated for 2 hours at 37°C. Then, wells were washed 
three times and incubated 1 h at room temperature with 1 pg/ml of RAB1.2 diluted in 
washing buffer. Anti-rabbit IgG labelled with horse-radish peroxidase (GE Healthcare) 
were then added (1/2000 in washing buffer) and incubated 1 h at room temperature. The 
plate was developed with TMB for 5 minutes and stopped with 1M H2S04 before reading 
at 450 nm. The same general protocol was used to test MoAb_E10 as a possible capturing 
antibody in a sandwich ELISA (see the result section 4.1.3).
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3.8 Generation of MSF expression vectors
The full length cDNA (2,192 bp, accession No. AJ535086.1) of human MSF subcloned 
into the BamHI site of pUC57 (2,710 bp) was obtained by GenScript.
The MSF cDNA insert was removed from pUC57 cloning vector (100 pg) by digestion 
with BamHI (60U) at 37°C overnight. The cDNA was purified from the agarose gel 
(Wizard SV Gel and PCR Clean-up System, Promega) and then ligated into pSG5 
expression vector (4,100bp), previously linearized with BamHI, to obtain the pSG5-MSF 
expression vector. The orientation of the cloned MSF was initially analysed by digestion 
with Xbal, and then confirmed by sequencing.
One Shot® TOP 10 Chemically Competent E. coli were transformed with pSG5-MSF in 
both the sense and anti-sense orientation and the plasmids were purified by PureYield™ 
Plasmid Midiprep System -  (Promega). CHO cells were transfected using FuGENE 
Transfection Reagent (Roche) following manufacturer’s instructions. Since the pSG5 
expression vector does not contain any selection marker, cells were co-transfected with 
pSV2neo plasmid, which confers resistance to geneticin (G418). Transfected cells were 
cultured for two weeks in the presence of G418 (800 pg/ml) and then cloned by limiting 
dilution. Sense (CHO-cll) and antisense (CHO-A3) clones were selected and used in this 
work. In addition CHO-cll was further subcloned by limiting dilution, and CHO-3E6 
clone, producing higher levels of MSF, was selected and used in some experiments (see 
section 4.1.2.2).
3.9 Purification of recombinant human MSF
To purify human MSF from the culture supernatant of transfected CHO cells we 
followed two different strategies of affinity chromatography based on the presence in MSF 
of an heparin-binding domain (Hep 1/Fib 1; Figure 8) or a gelatin-binding domain (Gel- 
BD).
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a) Batch affinity purification on Heparin-sepharose beads CL-6B. 10 ml of supernatant 
from CHO-cll transfected cells were concentrated 10 times using a VIVASPIN column 
(Sartorius Italy, Muggio, Italy), 30kDa MWCO (Molecular Weight Cut Off), and then 
dialyzed against Buffer E (0.1 M NaCl, 10 mM CaCl2, 50 mM Tris-HCl, pH 7.0). The 
concentrated supernatant was then incubated with 2ml of Heparin-sepharose beads CL- 
6B (GE-Healthcare), previously equilibrated overnight with Buffer E, at 4°C under 
rotation overnight. At the end of incubation the unbound material was removed by 
centrifugation and beads were washed 3 times with Buffer E and once with 20 mM 
sodium phosphate (1.64g Na2HP04-7 H20 , 0.47g NaH2P04, pH 7.0 in 1L with H20). 
MSF (Lot #1) was finally eluted using 0.5M NaCl - lOmM sodium-phosphate.
b) Affinity chromatography on Heparin-sepharose column followed by reverse phase 
HPLC. To obtain a greater amount of protein we purified 100 ml of supernatant from 
CHO-cll using a 20 ml column of Heparin-sepharose CL-6B. CHO-cll supernatant was 
diluted with equilibration/loading buffer (50mM Tris/HCl, 50mM NaCl, pH 7.4) before 
loading onto the column. The protein was eluted with a linear NaCl gradient (0.05-2 M 
NaCl in loading buffer (50mM Tris/HCl, 50mM NaCl, pH 7.4); 3ml-fractions were 
collected. All fractions were analysed by Western blot and indirect ELISA using rabbit 
antisera (see section 3.10). Fractions containing MSF were pooled and purified by 
Reverse-Phase High Performance Liquid Chromatography (RP-HPLC) using C-8 
Aquapore RP-300 column (PerkinElmer, Norwalk, CT) or Source 5 RPC column; 
(Amersham Biosciences) equilibrated with 0.01% (v/v) trifluoroacetic acid (TFA) in 
H20 . MSF (Lot # 2) was eluted with acetonitrile gradient (0-99.9% CH3CN - 0.4 ml- 
fractions in 0.1% TFA).
c) Affinity chromatography on Gelatin-sepharose column followed by SEC. 150 ml of 
supernatants from CHO-cll were loaded on a 1ml Gelatin-sepharose 4B column. The 
column was equilibrated with PBS*7' at the flow rate 0.2 ml/min and then washed with 12
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column volume of PBS'7' containing 1M NaCl followed by 50 mM NaAcetate, 200 mM 
NaBr, pH 5.0. Bound proteins were eluted with 50 mM NaAcetate, 1M NaBr pH 5.0, and 
concentrated with VIVASPIN 6 (10 kDa MWCO). The concentrated solution was then 
chromatographed on Superdex 200 10X300 Gel Filtration Column (GE Healthcare) 
equilibrated and eluted with PBS'7' at a flow rate of 0.5 ml/min (MSF Lot # 3).
d) Affinity chromatography on Gelatin-sepharose column followed by affinity 
chromatography on Heparin-sepharose column or SEC. For this purification we used 
CHO-3E6 cells derived from further subcloning of CHO-cll. 400 ml of supernatants 
from CHO-3E6 were loaded on a 5 ml Gelatin-sepharose 4B column. The column was 
equilibrated with PBS'7' at the flow rate 0.5 ml/min. After this step the column was 
washed with PBS'7'+ 1M NaCl and then with PBS'7'. Bound MSF was eluted using a two 
steps gradient: 200 mM Arginine (10 ml of final volume), and 1M Arginine pH 5.22 (24 
ml final volume). Eluted MSF was dialyzed against 50mM Tris-HCl, 50mM NaCl pH 7.4 
(40 ml final volume).
To separate MSF from contaminating FN1, 30 ml of eluted MSF were loaded on a 
Heparin-sepharose CL-6B column and eluted using a three step gradient of elution in 
three steps. Briefly, 50 mM Tris was used with the addition of three different 
concentrations of NaCl (0.5M, 1M and 2M). The eluted preparation (MSF Lot # 4) was 
dialyzed against PBS'7'and loaded onto Superdex 200 10X300 Gel Filtration Column (0.5 
ml/min).
In parallel, 10 ml of the eluted preparation from Gelatin-sepharose column were 
concentrated 20 times by VIVASPIN 30.000 (30 kDa MWCO) and directly loaded onto a 
Superdex 200 10X300 Gel Filtration Column with flow rate 0.5 ml/min (MSF lot # 5).
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3.10 Generation of polyclonal antibodies
Rabbit polyclonal antisera were generated by PRIMM immunizing rabbits with the 
synthetic peptide specific for human MSF detailed in section 3.1. Pre-immune serum was 
collected (1 ml/rabbit), then rabbits were challenged intraperitoneally (ip) with 300 [ig of 
the MSF-specific peptide conjugated to KLH (VSIPPRNLGYC) diluted in Complete 
Freund Adjuvant (CFA). Immunization was repeated at day 21, 28 and 35 with the peptide 
diluted in Incomplete Freund Adjuvant (IFA). Blood (40-50 ml/rabbit) from immunized 
rabbits was collected and tested by ELISA before the purification of specific antibodies. 
Polyclonal antibodies (pAbs) anti-MSF were purified by immunoaffmity on a CNBr- 
Sepharose column carrying the peptide.
3.11 Generation of monoclonal antibodies (mAb) against MSF
PRIMM was also involved in the generation of monoclonal antibodies against human 
MSF. Mice were immunized with a four-branched multiple antigenic peptide (MAP) 
(Figure 9) in which four copies of the MSF-specific peptide were conjugated through the a- 
and e- amino functional groups of lysine to an inert core. The result is a large 
macromolecule that does not require further conjugation to a carrier protein. Immunization 
and first evaluation of antibody titers by ELISA were performed by PRIMM, while fusion 
and screening of hybridomas was conducted in our laboratory.
Lys
Lys
P ep tid e
P ep tid e
Peptide
P ep tid e
Figure 9. Structure of MAP-peptide. The MAP (Multiple Antigenic Peptide) system utilizes the a -  and e- 
amino functional groups of lysine to form an inert core to which four chains of MSF-specific peptide are 
anchored.
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Based on ELISA the evaluation of antibody titers in the immunized animal, the spleen 
from one mice was collected and sent to our laboratory. Mouse splenocytes, obtained after 
dissociating spleens with a syringe needle, were fused with SP2/0 myeloma cells (5:1 
ratio) using polyethylene glycol 1550 (SERVA, Rome, Italy) (Manufacturer’s standards 
procedures) Cells were seeded in 96 well plates and selected using HAT medium (RPMI- 
1640 medium containing 10% FCS, 100 mg/mL streptomycin, 100 IU/mL penicillin, 100 
mM hypoxanthine, 16 mM thymidine, and 400 mM aminopterin). After 2 weeks, culture 
supernatants of surviving clones were screened for antibody reactivity and specificity by 
indirect ELISA on His-MSF. The screening was repeated twice and 5 out of 23 positive 
clones (6H3, 3D3, 4G4, 5H4, 6B10) were selected and subcloned two times by limiting 
dilution. The hybridomas were analysed by indirect ELISA against His-MSF, supernatant 
from CHO-3E6 cells and FN1. This allowed us to select 9 hybridomas recognizing 
recombinant MSF but not FN1.
3.12 Purification of monoclonal antibodies by protein G column
3-5xl06 cells from selected hybridomas were injected in the peritoneal cavity of CD1 
nude mice after pre-treatment 1 week before with 1 ml of Pristane (Sigma-Aldrich).
Ascites (approximately 5ml) were collected 10 days after injection of hybridomas and 
MSF-specific antibodies were purified by Protein G-sepharose 4 Fast Flow column 
(Pharmacia, Milan, Italy) by standard procedures. Briefly, protein G-sepharose columns (1 
ml column volume) were equilibrated with PBS+/+ and loaded with 1 ml of the different 
ascites diluted 1:3 in PBS. The flow-through was applied again onto the column and the 
procedure was repeated 3 times. MSF-specific antibodies were then eluted using 0.1 M 
Glycine-HCl pH 2.8 and immediately buffered using 1.5 M Tris-HCl pH8.8.
The isotype of the different monoclonal antibodies was determined using the Mouse 
Monoclonal Antibody Isotyping Test Kit MMT1 (Biorad).
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3.13 MSF expression in polarized macrophages
Human monocytes were isolated from buffy coats obtained from normal blood donors 
by Ficoll (Hystopaque-1077; Sigma-Aldrich) and Percoll (GE-Healtcare) gradient 
centrifugation as previously described (Solinas et al, 2010). Residual T and B cells were 
removed from monocytes by plastic adherence.
To obtain tumour-conditioned macrophages (TC-M<f>), 3xl06/ml monocytes were 
cultivated for 5 days in RPMI 1640 containing 5% FCS in the presence of 30% (v/v) of 
supernatant derived from human pancreatic carcinoma cell lines PT45 or PANC1 (Solinas 
et al, 2010). Cells were incubated for additional 24 h with LPS (100 ng/ml) and IFN-y (25 
ng/ml) or IL-4 (20 ng/ml; all from PeproTech) to obtain M l- or M2-polarized M4>, 
respectively. Total RNA extraction from MO was performed with TRIzol (Invitrogen). 
following manufacturer’s instructions. cDNA was synthesized using 1 pg of total RNA and 
the Gene Amp RNA PCR kit (Applied Biosystems) according to the manufacturer’s 
instructions. 40 ng of cDNA were used as template in a total reaction volume of 25 p i 
containing 12.5 pi Taq Polymerase RedMix (Bioline) and 0.5 pi of each primer (10 pM). 
The list of primers used to analyse MSF mRNA expression by PCR is reported in Table 1. 
The reactions were analysed on 1% (w/v) agarose gel.
3.14 Migration assay
Migration of human pancreatic tumour cells (PANC1) was evaluated using a transwell 
system with 8 pm pore size (6.5mm - Costar, Euroclone, Milan, Italy). For the migration 
assay cells were harvested by brief exposure to trypsin, extensively washed and 
resuspended in DMEM without FCS. Purified MSF was also diluted in DMEM without 
serum and added to the lower chambers of the 24-well format transwells, while 1% FCS in 
DMEM was used as positive control. Cancer cells (1 x 105) were added to the upper 
chamber of the transwell and incubated for 6-24 h at 37°C. At the end of the incubation, 
transwells were recovered and non-migrated cells were removed from the top of the
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membranes using cotton swabs. Filters were then fixed in methanol, and stained with Diff- 
Quick (Medion Diagnostics). Migrated cells were counted in 20 high-power oil-immersion 
fields (HPF). Each sample was analysed in triplicate and results are expressed as the mean 
number of migrated cells in 20 HPF ± SD.
The same protocol was used to investigate the migration of other cancer cell lines, 
namely a breast cancer cell line, MDA-MB231; some colon cancer cell lines, HT29, 
SW480 and SW620; and CHO-3E6 cells.
Migration of peripheral blood monocytes was evaluated using a chemotaxis 
microchamber technique as previously described (Locati et al, 2001). Briefly, 27 pi of 
control medium (RPMI 1640) or purified MSF were added to the lower wells of a 
chemotaxis chamber (Neuroprobe, Pleasanton, CA, U.S.A.). The cell suspension (50 pi of 
a solution containing 1.5xl06 monocytes/ml) was seeded in the upper chamber. The two 
compartments were separated by a PVP polycarbonate filter (5 mm pore size; 
Neuroprobe). The chamber was incubated at 37°C in humidified atmosphere in the 
presence of 5% C02 for 90 min. In these experimental conditions, using a PBMC 
suspension only monocytes migrate across the filter and are recovered on its lower side. At 
the end of incubation, filters were removed, stained with Diff Quick, and 5 HPF were 
counted. Each sample was analysed in triplicate and results are reported as mean migrated 
cells ± SD.
Migration of murine peritoneal exudate cells (PECs), mostly macrophages, was 
analysed essentially with the same protocol. Briefly, PECs were obtained from C56B1/6J 
female mice 24 h after intraperitoneal injection of PBS7 and adjusted to a concentration of 
2xl06 macrophages/ml. Five pi of this cell suspension were plated in the upper 
compartments of the microchamber. After 4 h at 37°C filters were removed and processed 
as described above for human monocytes.
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3.15 In vivo growth of MSF transfected cells
In vivo growth of cells expressing MSF (CHO-cll or CHO-3E6) and CHO-A3 was 
analysed in CB17/SCID female mice. A range of different amounts of cells (from 3xl06 to 
5xl04; as detailed in section 4.2.3) in 200ul of PBS"7' were injected into the left limb of 
mice. Tumour appearance was followed daily and tumours were measured by a calliper 
three times a week. Tumour volume was calculated following the formula: (dm2xDM)/2 
(dm: minor diameter; DM: major diameter). Some tumours were collected at different time 
from injection and fixed in OCT (Optimal Cutting Temperature compound) for 
immunohistochemical analysis.
3.16 Immunohistochemical analysis
MSF expression was evaluated in OCT-embedded tumors or in paraffin-embedded 
specimens of tumours from mice injected with MSF-expressing CHO-cells (5 pm-thick 
histologic sections) and in paraffin-embedded human tissue sections (3 pm-thick histologic 
sections) from lung, breast and colon cancer.
Immunohistochemical analysis o f mouse tumour sections
Sections from OCT-embedded tumor specimens were fixed in 4% (v/v) 
paraformaldehyde (PFA) for 15 minutes at room temperature (RT). Sections were washed 
with 0.05% Tween 20 in PBS"7' for 5 minutes and incubated with Peroxidase 1 (Biocare 
Medical, Space Import Export, Milan, Italy) for 5 minutes followed by incubation with 
Roden Block (Biocare Medical) for 30 minutes.
Sections were stained with primary antibodies diluted in Da Vinci Solution (Biocare 
Medical) for 1 hour at RT. As primary antibodies we used the rabbit polyclonal antiserum 
RAB 2.3 (5 pg/ml), and the murine monoclonal antibody MoAb_E10 (1.5 pg/ml) 
generated in our laboratory. After the incubation with primary antibodies the different 
sections were incubated (30 minutes at RT) with the appropriate HRP-conjugated 
secondary antibody, namely the anti-rabbit MACH-4 Universal HRP-Polymer (Biocare
69
Medical) for 30 minutes, or the Mouse-on-Mouse HRP-Polymer (Biocare Medical) for 30 
minutes, respectively. Color was developed using 3,3’-diaminobenzidine (DAB; BioCare 
Medical) free base as chromogen, and then the sections were counterstained with 
hematoxylin (Dako).
To identify macrophages, paraffin-embedded tissue samples were stained with F4/80 
(AbD Serotec). Before staining, sections were dewaxed in Xilene or Bioclear, with 2-3 
washes for 10 minutes each. After dewaxing, sections were hydrated with a rapid wash in 
ethanol (2 washes), ethanol 90% (v/v), ethanol 70% and then in water. Antigen unmasking 
was performed in a Decloaker Chamber in DIVA Buffer IX (Biocare Medical) for 3 
minutes at 125°C and 5 minutes at 90°C. Endogenous peroxidases were blocked with 
Peroxidized-1 (Biocare Medical) for 20 minutes or using 3% (v/v) hydrogen peroxide for 
20 minutes. After washing with PBS-/-, 0.05% Tween 20, non-specific binding sites were 
blocked with Rodent Block M solution (Biocare Medical) for 30 minutes. Sections were 
then incubated with monoclonal rat anti mouse F4/80 at 1 pg/ml overnight. Rat on mouse 
HRP polymer kit (for F4/80) was finally used to detect F4/80 staining. The reactions were 
developed with DAB. Slides were counterstained for 2 min with haematoxylin and 
mounted with mounting medium Eukitt.
Immunohistochemical analysis o f on human tumour sections
Paraffin-embedded human tissues sections were cut and kept overnight at 37°C. 
Sections were dewaxed in Xilen or Bioclear, as detailed above. Antigen unmasking was 
performed in a Decloaker Chamber in DIVA Buffer IX (Biocare Medical) for 3 minutes at 
125°C and 5 minutes at 90°C. After blocking endogenous peroxidases with Peroxidized-1 
or with 3% (v/v) hydrogen peroxide for 20 minutes, non-specific binding sites were 
blocked with Background Sniper solution (Biocare Medical) for 30 minutes. Human tissue 
samples were then stained with MoAb ElO (2.5 pg/ml for lh) to identify MSF, or with 
mouse monoclonal anti-human CD68 (Dako; 780 pg/ml for lh) to identify macrophages.
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Staining with CD68 does not require antigen unmasking. Immunostaining with Mo Ab El O 
or with CD68 was revealed following incubation with rabbit anti-mouse MACH1 Polymer- 
HRP (Biocare Medical) for 15 minutes. Then the reactions were developed with 3,3’- 
Diaminobenzide (DAB). Slides were counterstained for 2 min with haematoxylin and 
mounted with mounting medium Eukitt.
3.11 In situ hybridization
Sense and antisense mRNA probes for human MSF were designed using Primer3 
(Rozen & Skaletsky, 2000) and the sequences are reported in Table 2. The nucleotides in 
green indicate the T7 sequence (for the forward primer) and T3 sequence (for the reverse 
primer). The PCR product is 151 bp long.
Antisense and sense riboprobes labelled with S-UTP were generated by in vitro 
transcription with T3 and T7 RNA polymerases (Riboprobe Combination System T3/T7- 
Promega), following Manufacturer’s instructions. The template was digested with DNase I 
(Riboprobe Combination System T3/T7- Promega), and non-incorporated 35S-UTP and 
DNA were removed by chromatography using Sephadex G50 columns (Amersham- GE 
Healtcare).
Table 2. Primers used for in situ hybridization
Prim ers
' . ~
Sequence of P rim ers (5,-*-3’) bp
Forward 5 ’ -T A ATACG ACTC ACT AT AGGT ATCCC ACCC AG A A ACCTTG-3’
151
Reverse 5 ’-AATTAACCCTCACTAAAGGTTGACCACATATTG TTTGTTC ACT-3’
Amplicon size
The activity of each probe was adjusted to l x l 07 cpm/ml using hybridization buffer 
(50mM DTT, 10% (w/v) Dextran Sulfate, 50% (v/v) formamide, 0.3M NaCl, lOmM Tris- 
HC1 pH 7.6, lOmM NaH2P 0 4 pH 6.8, 5mM EDTA pH 8, 0.2% (w/v) Ficoll 400, 0.2% 
(w/v) polivinilpirrolidone). Paraffin-embedded sections were dewaxed in xylene and
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rehydrated in graded ethanol. Proteins were removed first by acid treatment, incubating 
sections in 0.2M HC1 for 15 min at RT, and then by incubating with 40 pg/ml proteinase K 
from Tritirachium album (Sigma-Aldrich) in 50 mM Tris-HCl pH7.6, 5 mM EDTA pH8.0, 
for 7 minutes at RT. Sections were then postfixed with 4% (w/v) PFA-PBS for 15 minutes 
at RT. Subsequently all sections were acetylated in order to neutralize positive charges, 
eliminating non-specific signals. Sections were then air-dried at RT before labelling with
o r  sr
S-labeled probes (1x10 cpm/slide in hybridization solution) incubating overnight at 50° 
C in a humidified chamber.
After hybridization, sections were washed 2 times (45 minutes at 65°C) with FS 
solution (2X SSC, 50% (v/v) formamide) and then 2 times (30 minutes at 37°C) with STE 
solution (2X SSC, 20 mM Tris-HCl pH7.6, ImM EDTA pH8.0). Sections were 
subsequently treated with RNase A (10 pg/ml in 0.5 M NaCl, 1 mm EDTA, 10 mm Tris- 
HCl, pH 7.2) for 30 minutes at 37° C to remove nonspecifically bound riboprobes. Finally 
sections were washed with STE solution for 10 minutes at 37°C and then 2 times with FS 
solution for 45 minutes at 65°C, before air-drying at RT. At this point sections were 
exposed to high performance autoradiography film (Amersham Hyperfilm -  GE 
Healthcare) for 3 days, then dipped in Kodak photo emulsion NTB-2 for 3 weeks. 
Development and fixation were performed according to the Kodak protocol, and the 
sections were counterstained with hematoxylin (Dako) before evaluation with the dark 
field condenser U-DCD (Olympus BX51).
3.18 Statistical analysis
Statistical analysis was performed using Graphpad Prism (Prism 4 for Windows, version 
4.03). Data were compared by unpaired two tailed Student’s t test or by one way Anova 
followed by Dunnett’s post-test. P values of < 0.05 were considered statistically 
significant. Linear regression analysis was used to construct a standard curve for the 
setting of a sandwich ELISA.
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4 RESULTS
The selective expression of MSF by M2-like polarized TAM suggested that this 
molecule could play a role in the tumour microenvironment (Solinas et al, 2009). This 
prompted us to analyse MSF in the context to tumour biology. Given that no commercial 
reagents (i.e. recombinant MSF or anti-MSF antibodies) were available, considerable 
efforts have been devoted to the characterization of reagents, either developed in-house or 
outsourced, useful for the investigation of the role of MSF in human tumours. Thus the 
Results section is divided into three parts, the first concerning the production and 
characterization of reagents, the second part describing the biological studies performed 
with recombinant MSF, and the last part concerning the evaluation of MSF expression in 
mouse and human tumours.
4.1 Characterization and production of new reagents for human MSF
4.1.1 Generation of rabbit polyclonal antibodies against MSF
Different lots of pAbs were developed by PRIMM immunizing rabbits with the specific 
MSF peptide (see section 3.10) and were used in the present study, i.e RAB1, RAB2, 
RAB1.2, RAB2.2, RAB1.3 and RAB2.3. Each lot was characterized by ELISA against the 
immobilized peptide (100 ng/well). Figure 10a reports a typical titration curve of RAB1 
and RAB2. The rabbit pAbs obtained do not recognize human fibronectin 1 (FN1) while 
they can recognize a recombinant fragment of human MSF (His-MSF; see below) 
produced by PRIMM (Figure 10b).
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Figure 10. Specificity of anti-MSF pAbs. Specificity and sensitivity of rabbit pAbs were analysed by 
ELISA, a) ELISA plates were coated with 100 ng/well of the synthetic peptide VSIPPRNLGY. Different 
concentrations of the two rabbit pAbs RAB1 and RAB2 were then added. Results are reported as mean 
OD450±SD of triplicate wells for each point, b) Specificity of pAbs anti-MSF was verified by ELISA. 
Different concentrations of His-MSF and FN1 were immobilized on plastic wells and incubated with RAB1 
or RAB2, used at lOpg/ml, or with a rabbit polyclonal antibody against human FN1 (ab299) used at 1 pg/ml. 
Results are reported as mean OD450±SD of triplicate wells.
Similar results were obtained with RAB1.2, RAB2.2, RAB1.3 and RAB2.3. (Figure 11a 
and b)
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Figure 11. Specificity of different lots of anti-MSF pAbs. Specificity of pAbs anti-MSF was verified by 
ELISA. Different concentrations of His-MSF and FN1 were immobilized on plastic wells and incubated with 
RAB1.2 and RAB 2.2, RAB 1.3 or RAB2.3 (all used at 10 pg/ml). Results are reported as mean OD450±SD 
of triplicate wells.
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4.1.2 Expression and purification of recombinant protein
4.1.2.1 Production o f a recombinant fragment o f MSF 
protein (His-MSF)
The His-MSF fragment produced by PRIMM (see section 3.1) is recognized in ELISA 
(Figure 10b; Figure 1 la  and 1 lb) and western blotting (Figure 12b) by the pAbs generated 
in the present study. As shown in the Figure 12a and b, both silver staining and western 
blot analysis identify the recombinant fragment His-MSF with an apparent molecular 
weight of 14 kDa, as expected. In addition, a upper band is evident, with an apparent 
molecular weight of 28 kDa, that likely represents a dimer of His-MSF due to the cross­
link between the cysteines included in its sequence.
R A B l (5 g g /m l) RAB2 (5 p g /m l)
Figure 12. Analysis of the recombinant fragment His-MSF. Recombinant human His-MSF was 
characterized by SDS-PAGE followed by silver staining or western blotting, a) Different quantities o f His- 
MSF (from 1000 to O.lng of total protein) were separated on 10% polyacrylamide gel and then silver stained, 
b) different quantities of His-MSF (from 2000 to 10 ng of total protein) were separated on 10% 
polyacrylamide gel and transferred to membranes for western blotting. Analysis was performed with RABl 
or RAB2 antibodies (both at 5pg/ml), as indicated.
4.1.2.2 Expression o f h uman recombinant MSF protein
The MSF cDNA insert (2,192bp) coding for human MSF was removed from pUC57 
vector by digestion with BamHI and was sub-cloned in pSG5 vector (4,100bp), previously 
linearized with BamHI, in order to obtain the pSG5-MSF expression vector. The 
orientation of the cloned MSF was initially analysed by digestion with Xbal (Figure 13a),
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and then confirmed by sequencing for two selected constructs identified to have insert in 
the sense or anti-sense orientations (Figure 13b). As shown in Figure 13c, after digestion 
with Xbal the sense orientation is characterized by two fragments, respectively of 1,617 bp 
and 4,675 bp, while the antisense orientation shows two fragments of 895 bp and 5,397 bp
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Figure 13. MSF expression vector, a) Schematic representation of pSG5-MSF expression vector: the 2.1 kb 
fragment of MSF has been cloned in the BamHI site of pSG5 (4.1 kb); b) schematic representation o f pSG5- 
MSF containing the insert in sense and antisense orientation, c) to verify the orientation different clones of 
pSG5-MSF were digested with Xbal and aliquots were separated on 1% agarose gel. Lanes 1 and 2: pSG5- 
MSF with the insert in the sense orientation; lane 3 and 4: pSG5-MSF with the insert in the antisense 
orientation. Expected length of the fragments obtained after digestion with Xbal are reported in Panel b.
To obtain recombinant human MSF, CHO cells were co-transfected with pSG5-MSF 
and pSV2-neo, that confers resistance to G418 (see section 3.8). Supernatants from over
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300 clones were analyzed by dot blot analysis. His-MSF (1 pg) was used for comparison. 
As evident in figure 14a, most of the clones did not produce appreciable levels of MSF, 
however we identified 24 clones showing MSF production. Given that MSF content in the 
supernatant of transfected clones was heterogeneous, we selected 6 clones with an apparent 
high MSF expression for further analysis. First we analyzed the supernatants by SDS- 
PAGE followed by western blot in order to verify the apparent molecular weight of the 
protein produced by transfected clones. Since at this stage we did not know the sensitivity 
of the polyclonal antibodies RABl and RAB2 for the full length MSF protein, incubation 
was performed with both the antibodies. Results reported in Figure 14b indicated that the 
most abundant protein has an apparent molecular weight of approximately 75 kDa, as 
expected on the basis of MSF protein sequence. In parallel two clones transfected with the 
anti-sense expression vector were analysed and clone CHO-A3 was selected for further 
experiments.
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Figure 14. Expression of human MSF protein, a) Dot blot analysis of supernatants from clones obtained 
by limiting dilution of transfected CHO-cells. Red circles identify some of the MSF positive clones. His- 
MSF (lp g ) was used as a positive control, b) Western blot analysis o f six clones producing MSF and two 
clones transfected with the anti-sense construct. MSF protein is identified using RABl and RAB2 polyclonal 
antiserum (each at 5pg/ml).
Clones 1, 9 and 20 showed the highest signal in western blot, thus supernatants from these 
clones were further analysed by indirect ELISA (Figure 15). To this aim the same cell 
number of clones 1, 9 and 20 were plated and supernatants were collected after 24 hrs.
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Figure 15 reports the results obtained with RABl and similar data were obtained when 
RAB2 was used (not shown). As evident in Figure 15 supernatants from the three sense 
clones (CHO-cll, CHO-cl9, CHO-cl20) but not from the antisense clone, contain MSF. In 
order to optimize the selection of a cloned cell population, CHO-cll was further sub­
cloned by limiting dilution. Two clones were identified, CHO-3E6 and CHO-3G4, both 
secreting MSF in the culture supernatant (Figure 16).
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Figure 15. ELISA on supernatants from transfected clones. His-MSF (10-100 ng) or the indicated 
dilutions of supernatants from three different positive clone (CHO-cl20, CHO-cll and CHO-cl9) and from 
CHO-A3 (anti-sense clone) were coated on plastic wells. Presence of MSF in the culture supernatants was 
revealed by incubation with RABl (10pg/ml). Results are reported as mean OD450±SD o f triplicate wells.
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Figure 16. ELISA on supernatants from selected transfected clones. Supernatants from CH O -cll, two 
derived subclones, CHO-3E6 and CHO-3G4, and antisense clone CHO-A3, were coated on plastic wells and 
the polyclonal antibody RAB2.3 (lpg/m l) was used to identify MSF. Results are reported as mean OD450±SD 
of triplicate wells. OD450 obtained when RAB2.3 was incubated in PBS-coated wells is reported as negative 
control.
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4.1.2.3 Purification o f MSF protein
MSF was purified from the supernatant of transfected cells taking advantage of the
presence of two different domains: the heparin binding domain and the gelatin-binding 
(Gel-BD) domain (Figure 7). In a preliminary experiment we tested the feasibility of a 
purification process using Heparin-sepharose beads. Ten ml of concentrated supernatant 
from CHO-cll were incubated with Heparin-Sepharose beads and bound proteins were 
eluted with 0.5M NaCl, lOmM sodium phosphate (pH 7.0). Eluted proteins were then 
separated by SDS-PAGE and analysed by silver staining and western blot (Figure 17a and
b). As shown in Figure 17b, a band with an apparent molecular weight of 75 kDa 
recognized by anti MSF pAbs is evident in lanes 5 and 6, where we loaded the fractions 
eluted from Heparin-Sepharose beads. This indicates that we were in fact able to partially 
purify human MSF. However, silver staining (Figure 17a) also showed that a series of 
contaminants were still present in fractions 5 and 6, suggesting that the protocol needed to 
be improved. In particular a band of approximately 50 kDa, present in the supernatant from 
CHO-cll cells (lane 1) is still evident in lanes 5 and 6, where eluted MSF has been loaded. 
Thus we took advantage of a long standing collaboration with Jo Van Damme and Sofie 
Struyf at the Rega Institute in Leuven, two experts in the field of chemokine purification, 
and with their help we set up a two-step purification protocol based on affinity 
chromatography on Heparin-Sepharose followed by reverse phase HPLC. Silver staining 
and western blot analysis (Figure 18a and b) of fractions 23 through 30 eluted after HPLC, 
showed a defined 75 kDa band correspondent to human MSF (lot 2), but again some 
contaminants with different molecular weights were still present (Figure 18a).
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Figure 17. Purification by affinity to heparin-sepharose. Supernatant from CHO-cll cells was 
concentrated 10 times and incubated with Heparin-Sepharose beads in a Eppendorf tube. After removal of 
the unbound material and washing with 1 ml of Buffer E, MSF was recovered by incubation with 0.5M NaCl 
- 10 mM sodium-phosphate (pH7.0). Samples were loaded on 10% polyacrylamide gels. Two gels were run 
in parallel, one was silver stained (a) and the other was transferred to a membrane for western blotting (b). 
RAB1+RAB2, both at 5 //g/ml were used to identify human MSF. Lanes are as follow: 1) supernatant from 
CHO-cll cells (20pl); 2) concentrated supernatant (40 pi); 3) Unbound material (40 pi); 4) washing with 
Buffer E (40 pi); 5) and 6) eluted MSF (40 pi); 7) supernatant from CHO-A3 cells (40 p i ) .
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Figure 18. Purification by Heparin-affinity chromatography and HPLC. Supernatant from CHO-cll was 
first separated on a Heparin-sepharose column. The eluted fractions containing MSF were further subjected 
to HPLC. Fractions 23 through 30 were eluted by HPLC and analysed by 10% SDS-PAGE. a) Silver 
staining of HPLC fractions. Red arrows indicate MSF (Lot 2). b) Western blot analysis of HPLC fractions 
performed with RABl .2+RAB2.2 polyclonal antisera (both at 5 /ig/ml).
To further improve the purification process, we tested an alternative strategy taking 
advantage of the presence in MSF of the high affinity Gel-BD domain. Therefore, 
supernatant from CHO-cll cells was purified by affinity chromatography on a Gelatin- 
Sepharose column followed by Size Exclusion Chromatography (SEC). Given that FN1
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also contains the Gel-BD and the heparin binding domains, this protein could represent a 
possible contaminant of our preparations. Thus we introduced SEC to separate the proteins 
considering their molecular weight, approximately 250 for FN1 and 75 for MSF. Silver 
staining performed on the different fractions of the purification process (Figure 19a) 
showed a sharp and relatively pure band at the expected molecular weight (75 kDa) in lane 
7 (lot 3), and western blot analysis confirmed that the band obtained was indeed human 
MSF (Figure 19b). Chromatogram of the purification process through Gelatin-Sepharose 
column is reported in Figure 19c.
A last strategy for MSF purification was based on a first step of affinity 
chromatography on Gelatin-sepharose 4B column followed either by affinity on Heparin- 
sepharose (Lot 4) or by SEC (Lot 5). As detailed in Section 3.9, 400 ml of supernatant 
from CHO-3E6 were loaded on the Gelatin-sepharose column. The column was washed 
first with 1M NaCl and then with PBS-/-. MSF was eluted with a two-step gradient of 
Arginine: the first step at 200 mM was not sufficient to recover the protein while the 
second step at 1 M Arginine allowed the detachment of MSF from Gelatin sepharose. The 
eluted MSF was dialyzed as detailed in section 3.9 and then loaded on Heparin-sepharose 
or SEC columns. Aliquots of the different steps of the purification processes were analysed 
on 10% SDS-PAGE in two parallel gels, one was silver stained (Figure 20a) and the other 
was transferred to a membrane for western blotting (Figure 20b). The silver staining 
performed on the different steps of the two purification processes showed a slight 
fibronectin contaminant in the fraction eluted from Heparin-sepharose column (Figure 20a 
-  lane 9). On the contrary, purification by SEC resulted in an almost pure preparation of 
MSF, as shown by the single band at the expected molecular weight observed by SDS- 
PAGE (Figure 20a -  lane 10). Western blot with RABl and RAB2 pAbs is reported in 
Figure 20b.
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Figure 19. Purification by Gelatin-affinity chromatography and SEC. Supernatant from CHO-cll cells 
was purified by affinity chromatography on Gelatin-Sepharose column. After removal of the unbound 
material, MSF was eluted with 50 mM Na-acetate, 1M NaBr. Samples of the different steps were analysed by 
10% SDS-PAGE. a) Silver staining b) western blot performed with RAB1+RAB2 polyclonal antisera (both 
at 5 (.ig/ml). c) chromatogram of the purification through Gelatin column.
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Figure 20. Purification by affinity chromatography on Gelatin-sepharose 4B column followed either by 
affinity chromatography on Heparin-sepharose CL-6B column or by SEC. Aliquots of the different steps 
o f the two purification processes were loaded on 10% SDS-PAGE. a) Silver staining b) western blot 
performed with RAB1+RAB2 pAbs (both at 5 pg/ml). Lanes are as follow: 1) input Gelatin-sepharose 
column (supernatant from CHO-3E6); 2) unbound material (Gelatin-sepharose column); 3 & 4) washing 
respectively with 1M NaCl and PBS-/-; 5) 1st step with Arginine (200mM); 6 ) 2nd step with Arginine (1M); 
7) input Heparin or SEC column (protein eluted with 1 M Arginine and dialyzed); 8 ) unbound material 
(Heparin-sepharose column); 9) MSF eluted from Heparin-sepharose column; 10) MSF eluted from SEC.
In summary, the different lots of purified MSF are reported in Table 3.
CHO-cll
Affinity purification on 
Heparin-sepharose beads 
CL-6B
118 pg/ml 
(118 pg tot.)
CHO-cll
Affinity chromatography 
on Heparin-sepharose 
beads CL-6B
RP-HPLC (Reverse-Phase High 
Performance Liquid 
Chromatography)
n.d.*
CHO-cll
Affinity chromatography 
on Gelatin-sepharose 4B 
column
SEC (Size Exclusion 
Chromatography)
47 pg/ml 
(23 pg tot.)
CHO-3E6
Affinity chromatography 
on Gelatin-sepharose 4B 
column
Affinity chromatography on 
Heparin-sepharose beads CL- 
6B
100 pg/ml 
(lOOpg tot.)
CHO-3E6
Affinity chromatography 
on Gelatin-sepharose 4B 
column
SEC (Size Exclusion 
chromatography)
10 pg/ml 
(35 pg tot.)
*n.d : not determined
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4.1.3 Generation and purification of mouse monoclonal antibodies 
against MSF
No monoclonal antibodies against human MSF are commercially available, thus the 
generation of such reagents has been fundamental to the success of the project.
Two different mouse monoclonal antibodies are described: a mouse monoclonal 
antibody (mab7.1) was raised against the MSF-specific decapeptide. The epitope 
recognized by mab7.1 was identified as PPRNLGY by pepscan analysis (Schor et al, 
2003). A second mouse monoclonal antibody described (1D2 antibody) was generated by 
Hu H. and colleagues (Hu et al, 2009). In this case the monoclonal antibody reacted 
strongly with cell surface antigens of human esophageal cancer endothelial cells (HECEC) 
and was selected because could influence their migratory behaviour (Hu et al, 2009).
Given the high identity between human MSF and FN1, and between human and murine 
FN1, the generation of monoclonal antibodies represented a big challenge. For this reason 
we outsourced part of the work to PRIMM, who defined and produced the immunogens, 
performed immunizations and evaluated the response of mice to the challenge; instead, the 
screening of hybridomas was performed in our laboratory. Animals were immunized with 
a branched version of the decapeptide (MAP-peptide) synthetized by PRIMM (see section 
3.11). Antibody titers were evaluated initially by PRIMM and subsequently in our 
laboratory. Data reported in Figure 21 refers to a titration experiment by ELISA performed 
in our laboratory and reports the data obtained with sera from two animals with results 
essentially similar to those obtained by PRIMM (not shown).
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m ouse #3 
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m ouse #3 pre-immune 
m ouse #4 pre-immune
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Figure 21. Screening of sera from mice immunized with MAP-peptide. ELISA with of sera obtained 
from Balb/c mice immunized with MAP-peptide. His-MSF (lpg/well) was immobilized onto plastic wells 
and different dilutions of sera from immunized mice were added. Each point represents mean OD4 5 0  ± SD of 
triplicate wells.
Splenocytes were obtained from an immunized mouse with a satisfactory titer and fused 
with SP2/0 myeloma. The first screening of the fusion was conducted by ELISA on 
immobilized His-MSF. In total we analysed supernatants from 616 wells. To select the 
hybridomas producing anti-MSF antibodies we classified the clones comparing OD450 to
PBS, as indicated in Table 4.
■ ' . ...  ' ...~.— —........ ...... . ........ .. ..
T a b l e  4 .  P r o d u c t i o n  o f  a n t i -M S F  a n t i b o d i e s  f r o m  h y b r i d o m a s .
: - • •
R e s p o n s e 1
N o w e l l s  /  P l a t e P e r c e n t a g e  
o n  t o t a l  
w e l l s 31 2 3 4 5 6 7
A b s e n t Basel ine2 87 85 86 84 83 86 87 97.1
Low Twice base l ine 1 2 3 2 1 1 1.6
M e d i u m
Th re e  t o  five t i m e  
basel ine
1 1 1 0.5
High > five t i m e  base l ine 1 1 1 2 0.8
1 Response was classified comparing OD450 obtained with supernatants from hybridomas and 
baseline.
2 Baseline refers to PBS used instead of supernatant from hybridomas (range OD450 0.15 - 0.5).
3 Total wells analyzed in seven plates were 616.
As shown in Table 4, most of the hybridomas did not produce anti-MSF antibodies, 
while five hybridomas showed a high response in terms of OD4 5 0 . This analysis was 
repeated a second time for 27 selected hybridomas representative of the different levels of
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response, and results of the two ELISA are reported in Figure 22. Among the twenty seven 
hybridomas, the five showing a high response in the two ELISA assay (3D3, 4G4, 5H4, 
6B10, 6H3) were sub-cloned at 5 cells/well. Growing clones were tested again in ELISA. 
Five clones were selected following the criteria detailed above, and subcloned at 1 
cell/well. From this second subcloning, we obtained in total almost 118 clones that were 
tested in ELISA on His-MSF, recombinant MSF and FN1. Twelve hybridomas, 
recognizing His-MSF and recombinant MSF, but not FN1, were finally selected (Figure 
23). To increase the amount of antibody production, we injected hybridomas into CD-I 
nude mice. To this purpose we to injected nine of the hybridomas reported in Figure 23. 
After 1 week, ascites fluids were recovered and tested by indirect ELISA on His-MSF 
(Figure 24).
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Figure 22.Screening of supernatants from 27 selected hybridomas. Supernatants from hybridomas were 
analyzed by indirect ELISA on wells coated with His-MSF (lpg/w ell). The experiment was repeated twice 
with supernatants collected in two different days to confirm reproducibility o f the results. Five positive 
clones (circle) were selected and further subcloned .
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Figure 23. Final screening of monoclonal antibodies. Clones were analysed by indirect ELISA against 
His-MSF, MSF full-length and human FNl immobilized onto plastic wells (lpg/w ell).
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Figure 24. Titration of ascites fluids. Ascites fluids were titrated by indirect ELISA on His-MSF (lpg/well) 
immobilized on plastic wells. Different dilutions of the ascites collected from mice were tested. Results are 
expressed as mean OD4 50 ±SD of triplicate wells.
A first group of antibodies in ascites fluids were purified by protein G sepharose. Figure 
25 reports the titration curve by direct ELISA of M oA bElO , MoAb_C8 and MoAb_F2. 
Coating was performed with different dilutions of supernatant from CHO-3E6 cells, while 
purified antibodies were all used at 1 pg/ml. MoAb_E10 resulted to have the best titer 
while MoAb_F2 and MoAb_C8 showed a lower efficiency in the recognition of 
recombinant MSF. Thus MoAb_E10 was selected for further experiments. Analysis of the 
isotype indicated that MoAb-ElO is an IgM.
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Figure 25. Titration of purified antibodies on full-length MSF. Purified MoAb ElO, MoAb_C8 , 
MoAb_F2 (1 pg/ml) were plated on wells coated with different dilutions of supernatant from CHO-3E6 cells. 
Each sample was analysed in triplicate and data are expressed as mean OD4 5 0 ± S D .
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4.1.4 Development of a sandwich ELISA to quantify MSF in 
biological fluids
In order to quantify MSF in biological fluids we tried to optimize a sandwich ELISA 
specific for the protein. Among the different combinations of antibodies tested, optimal 
results were obtained with two capturing antibodies: a commercial monoclonal antibody 
recognizing the Gel-BD domain of human FN1, that is also conserved in MSF 
(MAB1892), and the murine MoAb_E10 developed in our laboratory. The rabbit antiserum 
RABl.2, that does not recognize FN1, was used to detect captured MSF. Recombinant 
MSF purified by affinity chromatography on Gelatin-Sepharose followed by SEC (Lot 3) 
was used as standard (0.02-2.5 pg/ml). Figure 26 shows the standard curve obtained when 
MAB1892 was used to capture MSF and RABl.2 to detect bound MSF.
Figure 26. Standard curve with 
purified MSF. Plates were coated with 
MAB1892 (100 ng/well) and different 
concentrations o f MSF (Lot 3) were 
used to generate a standard curve. 
R A B l.2 was used to detect bound MSF. 
Range o f linearity was between 0.02 
and 2.5 jig/ml (r2= 0.9528; p<0.01).
The assay developed has a sensitivity of approximately 30 ng/ml. With this set up, we 
were able to detect MSF in the supernatants of transfected CHO cells, while there was no 
signal detected when supernatants of anti-sense transfected CHO cells (CHO-A3) were 
used as control (Figure 27a). This experiment confirmed that FN1, that is also present in 
the culture supernatants of CHO cells and is captured by MAB1892, is not recognized in 
this setting (Figure 27a). Contrary to this, FN1 was detected in both the supernatants from 
CHO-cll and CHO-A3 when the rabbit polyclonal antibody ab299, recognizing human
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FN1, was used to detect bound proteins (Figure 27b). In this case also FN1 captured by 
MAB1892 is detected, as expected, by ab299. As baseline, wells coated with MAB1892 
were incubated with PBS and then with RA Bl.2 or ab299. One way Anova with Dunnett's 
multiple comparison test was used to compare baseline OD450 obtained with PBS with 
those obtained with supernatants from CHO-cll and CHO-A3 cells or FN1 (* p<0.05; **
p<0.01).
ab299RAB1.2
C D  control 
■■CHO-cll 
■ ■ C H O  A3
Figure 27. Detection of MSF in the supernatants of transfected CHO-cells by sandwich ELISA. Wells 
were coated with M A B 1892 and then incubated with various dilutions of culture supernatants from CHO-cl 1 
and CHO-A3 (control) cells and human purified FN 1. Detection of bound proteins was performed with a) 
R A B l.2 (anti human MSF) or b) ab299 (anti human FN1). Baseline is represented by wells coated with 
MAB1892 and then incubated with the appropriate detection antibody. Results are expressed as mean OD4 50  
nm ± SD of triplicate wells. * p<0.05; ** p<0.01, (one way Anova with Dunnett's multiple comparison test) 
compared to PBS.
Using this experimental set up we made an initial estimation of the amount of MSF 
produced by CHO-cll, which resulted to be approximately 8 pg/ml, and by CHO-3E6, that 
resulted to be approximately 40 pg/ml. This assay was also used to quantify MSF protein 
in biological fluids (plasma vs serum) of healthy donors. Initial experiments indicated that 
MSF can be detected in 5 out 7 plasma samples (Table 5). In this small group of subjects 
analysed, two of them had undetectable levels of MSF, four of them had a level in the 
range between 20 and 51 ng/ml, and one plasma sample had approximately a ten times 
higher amount of MSF (221 ng/ml). In addition this assay was not able to measure MSF in 
serum, with the exception of one subject (Table 5).
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Table 5. MSF levels in plasma and serum of
healthy subjects measured by sandwich 
ELISA
Subject No Plasma(ng/ml)
Serum
(ng/ml)
1 22.9 ND*
2 ND ND
3 221.1 43.5
4 50.9 ND
5 28.1 ND
6 25.1 ND
7 ND ND
*not detectable
MoAb ElO was also investigated as the capturing antibody in the sandwich ELISA. 
His-MSF and purified recombinant MSF (Lot 4) were used for the standard curve and 
bound proteins were detected with R A Bl.2. With this setting we were able to detect His- 
MSF (Figure 28) with a sensitivity of approximately 40 ng/ml however the detection of 
purified MSF was poor and the lower limit of detection was 1.2 pg/ml (data not shown).
His-MSF [pg/ml]
Figure 28. Standard curve with His- 
MSF. Plates were coated with MoAb_E10 
( 1 0  |.ig/ml) and different concentrations of 
His-MSF were used to generate a standard 
curve. R A B l.2 was used to detect bound 
MSF. The range of linearity was between 
0.04 and 2.5 pg/ml (r2= 0.9822; p<0.01).
In summary we have synthetized and purified recombinant MSF and developed a 
monoclonal antibody (MoAb ElO) that recognizes specifically MSF. In addition we were 
able to set up a preliminary assay for the measurement of MSF in biological fluids. The 
reagents developed are suitable for the characterization of some of the biological properties 
of MSF and the monoclonal antibodies obtained can be tested in immunohistochemistry to
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investigate MSF expression in human tumours. Sections 4.2 and 4.3 will describe the 
results obtained with these reagents.
4.2 Biological studies on human MSF
Once having available transfected cells expressing human MSF, purified recombinant
MSF and monoclonal /polyclonal antibodies recognizing human MSF, we addressed more 
deeply the possible involvement of MSF in cancer. In particular we focused our attention 
on the motogenic properties of MSF and on the possible pro-tumoral role of this protein.
4.2.1 MSF expression in macrophages and cancer cells.
Solinas et al. (2010) found by transcriptional profiling that human MSF is expressed by 
M2-polarized macrophages. To confirm this finding, we induced macrophage 
differentiation from peripheral blood monocytes using conditioned medium from tumour 
cells (TC-MO). Macrophages were further polarized toward Ml or M2 phenotype by 
exposure to LPS and IFN-y or IL-4 respectively. To evaluate MSF expression, total RNA 
was extracted and analysed by PCR using two sets of primers: CL1, amplifying a sequence 
present in the 5’ end of both MSF and FN1, and CL2, amplifying a sequence specific for 
the 3’ end of MSF (see section 3.1 and Table 1). As shown in Figure 29, the 1448 bp 
product amplified by CL2 primers is present only in TC-MO and in M2-polarized 
macrophages but not in Ml cells. On the contrary, the 771 bp fragment amplified by CL1 
primers is present in all samples analysed. Therefore, while all monocytes and 
macrophages express FN1, only M2 and TC-MO express MSF, the former at an apparent 
higher level.
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Figure 29. MSF expression in TC-MO. Agarose gel electrophoresis o f amplified DNA from monocytes, 
TC-MO and polarized macrophages.
In addition, since MSF is also produced by tumour cells (Schor & Schor, 2010), 
expression was measured by RT-qPCR in human cancer cell lines of different origin 
(Figure 30). Here it was found that MSF was highly expressed in 8387 fibrosarcoma and in 
MDA-MB231 breast carcinoma, whereas other human cancer cell lines showed very low 
(or no) expression. These results suggest that MSF might be expressed in a tissue (and 
tumour) specific manner. The finding of MSF expression in M2 and M2-like macrophages 
as well as in tumour cells, might suggest a role in the regulation of tumour maintenance.
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Figure 30. MSF expression in human cancer cell lines. RT-qPCR was used to quantify MSF expression in 
the indicated human cancer cell lines. Results are normalized to GAPDH expression. Each sample was 
analysed in triplicate and data are expressed as mean 2"Act±SE M .
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4.2.2 Motogenic activity of human MSF
Having available a small amount of recombinant MSF, we investigated its biological 
properties focusing initially on the motogenic activity. The transwell migration assay was 
used to evaluate the motogenic activity of MSF on Panel tumour cells, as described by 
Solinas et al. (2010) A first set of experiments was performed to set up the optimal 
conditions for Panel migration. Different incubation times (6 and 24 hours) and different 
concentrations of FCS (1% and 10%) as positive control for the assay were used. As can be 
seen in Figure 31, 1% FCS had the best effect in the induction of Panel migration. Given 
the higher number of migrated cells after 24 h incubation at 37°C, we opted for a 6 h
Figure 31. Migration of Panel cells. Migration of 
Panel cells was analysed using transwell plates. 1% and 
10% FCS were used as a positive control. 105 Panel 
cells were allowed to migrate for 6  and 24 h at 37°C. 
Results are expressed as mean number ± SEM of cells 
migrated in 20 HPF.
Once the optimal setting was defined, we tested the effect of partially purified MSF 
(Lot 1) on migration of Panel cells. Lot 1 was used at a dilution of 1/6 or 1/12; as control 
supernatant from CHO-A3 was treated in the same way and the fraction eluted from 
Heparin-sepharose with 1M NaCl was tested at a 1/6 and 1/12 dilutions. As shown in 
Figure 32, MSF Lot 1 induces the migration of Panel cells to levels comparable to the 
migration observed with 1% FCS used as positive control. In the same setting, no 
motogenic effect is evident when similar dilutions of a comparable fraction from CHO-A3 
cells or NaCl were tested. These results confirmed the motogenic activity of our purified 
MSF protein.
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Figure 32. Motogenic activity of 
human MSF. Panel cells (105) were 
placed in the upper compartment of a 
transwell and incubated 6 h at 37°C. 
Supernatant from CHO-A3 cells 
purified through Heparin-sepharose 
and NaCl (originally 1M) used for the 
elution of Heparin-sepharose column 
were tested as negative control at the 
same dilution used for MSF Lot 1.1% 
FCS was used as positive control. Data 
are reported as mean number ± SEM, 
of migrated cells in 20 HPF. Each 
condition was tested in triplicate
We then moved to analyse the migration of monocytes toward purified MSF. 
Monocytes from healthy donors were allowed to migrate in a Boyden microchamber to 
different concentrations of purified MSF (1 -  100 pg/ml correspondent to 0.013 nM-1.3 
nM considering a molecular weight of 75kDa) for 90 minutes at 37°C. Both preparations, 
purified respectively by affinity chromatography on Gelatin sepharose and then Fleparin- 
Sepharose (Lot 4) or SEC (Lot 5) were used. Figure 33a shows the results obtained with 
MSF Lot 4: migration was observed with 10 pg/ml of MSF. The number of migrated 
monocytes was only slightly lower than the response to the supernatant from 8387 cells, a 
known source of MCP1/CCL2 used as positive control for monocyte migration.
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Figure 33. Migration of monocytes to purified human MSF. Monocytes were plated in the upper 
compartment of a Boyden microchamber while stimuli were added in the lower compartments. Negative and 
positive controls were respectively RPMI w/o FCS and supernatant from 8387 fibrosarcoma cells as source 
of CCL2/MCP1. a) MSF lot 4 and b) MSF lot 5 were tested at 100, 10 and 1 pg/ml. Each sample was 
analysed in triplicate or duplicate and data are expressed as mean number of migrated cells in 20 HPF ±  
SEM. Student's t test was used to compare migration to MSF or Sup 8387 and baseline migration to RPMI 
w/o FCS. * p<0.05; ** p<0.01; *** p<0.0001 compared to RPMI in the respective experiment.
When MSF lot 5 was used similar results were obtained, with a significant migration to 
100 and 10 pg/ml of purified MSF (Figure 33b).
We also analysed the effect of endogenous MSF on cell motility. Initially we analysed 
the migratory behaviour of transfected CHO-3E6 cells compared to wild type CHO cells 
and we observed that the transfected CHO-3E6 cells, producing recombinant MSF, 
migrated more efficiently than wild type cells to a stimulus such as 1% FCS (Figure 34a).
Figure 34 Motility of CHO and 
human cancer cell lines. Migratory 
response of cells to 1% FCS. a) 
migration of CHO-WT and CHO-3E6 
cells; b) migration of human cancer 
cell lines.
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In addition, we tested some of the cancer cell lines expressing different levels of MSF, 
as evaluated by RT-qPCR (Figure 30). As shown in Figure 34b, some of the cancer cell 
lines tested migrate to 1% FCS. Interestingly, a significant correlation was found between 
the levels of MSF expression evaluated by RT-qPCR and the migratory response (Pearson 
r=0.9462; p=0.015) (Figure 35).
Figure 35. Correlation 
between MSF mRNA 
expression and migratory 
response of tumor cells.
Migratory response o f cells to 
1% FCS was correlated to the 
expression o f MSF mRNA. A 
significant correlation
(Pearson r=0.9462, P=0.015) 
was observed.
4.2.3 In vivo transplantation of MSF transfected tumour cells
To investigate a possible cancer promoting role of MSF we took advantage of the 
transfected CHO cells expressing MSF (CHO-cll and CHO-3E6). Given our observation 
on MSF expression in M2-like pro-tumoral macrophages, we expected that MSF 
expression could eventually increase macrophage recruitment in the tumour. Thus we first 
investigated whether human MSF could exert its properties on murine macrophages. To 
this aim we performed a chemotaxis experiment with murine peritoneal macrophages. As 
shown in Figure 36, murine peritoneal macrophages can significantly migrate in response 
to both Lot 4 and Lot 5 of human MSF.
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Figure 36. Migration of mouse peritoneal macrophages to human MSF. Macrophages were plated in the 
upper compartment of a microchamber. Lower wells contained RPMI w/o FCS as negative control and 
supernatant from CHO 3E6 cell (sup) as positive control. Different concentration of purified MSF from 
1000 to 0.01 ng/ml (in green Lot 4 and in blue Lot 5) were tested. After 4 h incubation at 37°C cells in 5 HPF 
were counted.. * p<0.05; ** p<0.01, one way Anova.
CHO-cll and CHO wild type cells were then injected in SCID mice, and the in-vivo 
growth of tumours followed over time. In a first experiment mice were injected with 3x106 
cells from each cell line. In that case the tumours appeared very rapidly (latency time 
approximately 8-10 days) in all the animals without appreciable differences in tumour 
takes. Despite this, we found a significant difference (p<0.05 Student's t test) in tumour 
volumes between CHO-WT and CHO-cll at day 16, 19 and 21 after transplantation 
(Figure 37a). The experiment was then conducted with 5xl05 and 5xl04 cells: no 
significant differences in latency and tumour growth were observed when mice were 
treated with 5xl05 cells (Figure 37b), but there was a trend toward a higher growth rate for 
CHO-cll cells.
When mice were treated with 5x104 cells, a significant difference (p<0.05) in tumour 
growth between CHO-cll and CHO-WT cells was observed at day 21, 24 and 36 after 
transplantation (Figure 38), while no differences in latency were observed. Given these 
results we treated mice with CHO-3E6, that can produce 5 times more MSF compared to 
CHO-cll. Mice were treated intramuscularly with 5xl04 CHO-3E6 cells and CHO-WT 
cells. A significant difference (***p<0.001) in tumour growth between the two groups was 
observed at day 16, 18, 21, 24 (Figure 39). Similarly, when mice were treated with 5x10 ,
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a tendency for higher growth rate of tumours derived from MSF-expressing cells was 
observed but difference was statistically significant only at day 31 (not shown).
The expression of MSF in tumours derived from CHO-WT or CHO-3E6 cells was 
evaluated by PCR. Tumours were excised from the animals at day 24 and results of the 
PCR analysis are reported in Figure 40. cDNA, retrotranscribed from total RNA extracted 
from tumours derived from CHO-WT (lanes 1-8) or CHO-3E6 (lanes 9-16) cells, was 
amplified with primers for human MSF and for hamster FN1. As shown in Figure 40, 
tumours derived from CHO-3E6 cells express human MSF even after 24 days of growth in 
mice. All the tumours express, as expected, hamster FN1.
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Figure 37. In  vivo growth of CHO-cll and CHO-WT cells. CHO-cll (n=7) and CHO-WT (n=7) were 
injected intramuscularly in CB17/SCID. Two different doses were used 3x l0 6 (panel a) and 5xlCf (panel b). 
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Figure 38. In vivo growth of CHO-cll and CHO-WT cells. CB17/SC1D Mice were injected 
intramuscularly with 5xl0 4 CHO-WT (empty circle, n=7) or CHO-cll (red circle, n=7) cells. Tumour 
volume was measured at the indicated time points. Volumes measured for each animal are reported, black 
line represent the mean volume ±SEM for each group and time point. (*p<0,05 Student’s t test).
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Figure 39. In vivo growth of CHO-3E6 and CHO-WT cells. Mice were injected intramuscularly with 
5x104 CHO-WT (empty circle, n= 8 ) and CHO-3E6 (red circle, n=8 ) cells. Tumour volume was measured at 
the indicated time points and volumes measured for each animal are reported. Black line represents the mean 
volume ±SEM for each group and time point. (***p<0,001).
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Figure 40. MSF expression in tumours derived from CHO-3E6 and CHO-WT cells. Tumours from 
different animals (each number represent a mice) were excised at day 24 after intramuscular injection with 
5x l0 4 CHO-WT or CHO-3E6 cells. cDNA obtained by retrotranscription of total RNA was amplified 
analysed by agarose gel electrophoresis to evaluate expression of human MSF and hamster Fibronectin.
4.3 MSF expression in mouse and human tumours
Given the selective expression of MSF by M2 macrophages and M2-like TAMs we were 
interested to investigate MSF expression in human tumours. We thus took advantage of the 
polyclonal and monoclonal antibodies developed in this thesis to investigate MSF 
expression in tumour tissues.
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4.3.1 Immunohistochemical analysis of MSF expression in mouse 
model
Initially we analysed MSF expression in sections from the tumours derived from CHO- 
WT and CHO-3E6 cells transplanted in vivo. Two antibodies were used, namely RAB2.3 
and MoAb_E10. Tumours were analysed at day 24 after injection. A positive signal was 
observed after staining with RAB2.3 of tumor sections derived from CHO-3E6, while 
sections from CHO-WT tumors were substantially negative (Figure 41a). A similar 
scattered staining was observed when the monoclonal antibody MoAb_E10 was used 
(Figure 41b). Different mechanisms could explain the higher growth rate of tumours 
derived from MSF-expressing cells compared to CHO-WT. It is known and we confirmed 
here that MSF has a motogenic activity for different cells (Schor & Schor, 2010) and in 
particular we showed that MSF can attract macrophages (e.g. Figure 36). Thus we 
analysed the expression of F4/80, a well-known macrophage marker, in tumours derived 
from CHO-WT and CHO-3E6 cells. However no differences were observed in terms of 
percentage of F4/80+ cells evaluated by FACS (not shown), nor in term of F4/80 positive 
area evaluated by immunohistochemistry (Figure 42). Since MSF has also been described 
as pro-angiogenic factor (Schor et al, 2001), it would be interesting to analyse the 
expression of CD31, a marker of endothelial cells, in tissue samples from tumours derived 
by injection of CHO-WT and CHO-3E6 cells. However preliminary results on three 
tumours did not show any significant difference in the levels of CD31 positive cells (data 
not shown), and further experiments will be necessary to address this point.
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Figure 41. Immunohistochemical analysis of MSF expression in tumours derived from CHO-WT and 
CHO-3E6 cells. Tumours were excised 24 days after injection of CHO-WT and CHO-3E6 cells in mice. 
Tumour sections (lOx) were stained with a) RAB2.3 (5 pg/ml) or b) MoAb ElO (1,5 irg/ml). DAB was used 
to develop the staining. Arrows indicate some MSF expressing cells (brown); inserts are higher 
magnifications of selected areas.
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Figure 42. Percentage of F4/80 positive cells.
Analysis of F4/80 positive area /fields on sections 
from tumours derived from CHO-WT and CHO-3E6 
cells. Black lines represent median values of the two 
distributions.
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4.3.1 Immunohistochemical analysis of MSF expression in human 
tumours
We then proceeded to analyze MSF expression in formalin-fixed and paraffin- 
embedded human primary lung, breast and colorectal cancers with MoAb_E10. Tumoral as 
well as stromal cells were immunoreactive in all analysed tissues. In tumoral cells MSF is 
heterogeneously expressed. A preliminary evaluation performed by an expert histologist 
indicate that endothelial cells lining blood vessels, cancer-associated fibroblasts (CAFs), 
and a subset of immune cells of the innate system also express MSF (Figure 43). These 
observations need to be confirmed by further experiments identifying with certainty the 
cells expressing MSF in tissue sections. Interestingly, in both lung and breast cancer 
CD68+ infiltrating macrophages were also immunoreactive for MSF. In the adjacent 
alveolar tissue, macrophages were found immunoreactive for both CD68 and MSF (Figure 
44)
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Figure 43. Immunohistochemical analysis of MSF expression in tumours derived from human breast 
ductal adenocarcinoma, colon carcinoma and non-small cells lung cancer. Tumour sections were stained 
with MoAb_E10 (2.5 pg/ml). a) breast ductal adenocarcinoma (lOx); b) colon carcinoma (lOx); c) non-small 
cells lung cancer (lOx). d) & e) are 20x images of non-small cells lung cancer: endothelial and stromal 
component (d), and stromal and immune cells (e).
CD68+ MoAb E10
Adjacent alveolar tissue to lung tumour
Figure 44. Immunohistochemical analysis of MSF expression in alveolar tissue adjacent to tumour 
area in lung cancer. Tumour sections were stained with anti-CD68 (780 pg/ml) and MoAb E10 (2.5 
pg/ml). Alveolar tissue adjacent to tumour area shows alveolar macrophages (CD68+) that express MSF 
protein.
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4.3.2 In situ hybridization on tumour tissues
To confirm the wide staining with MoAb_E10 observed in different tumour specimens, 
we performed in situ hybridization (ISH). CHO-3E6 cells and CHO-A3 were transplanted 
into recipient mice and tumours were excised 24 days after injection. Tissue sections of 
tumours derived from both CHO-A3 and CHO-3E6 cells were prepared and processed for 
ISH. As shown in Figure 45, a clear signal was detectable in sections derived from CHO- 
3E6 hybridized with MSF antisense probe, whereas no signal was observed with MSF 
sense probe on all tissue sections, irrespective of whether they were derived from CHO- 
WT or CHO-3E6 tumours. These results indicate that ISH represents an useful assay to 
evaluate MSF expression in tumour tissues. Therefore, we performed ISH on human breast 
cancer samples obtained from the Pathological Anatomy Department, Humanitas Clinical 
and Research Center, Milan, Italy. In these samples derived from human histological 
sections we found high levels of MSF expression in transformed cells (Figure 46), 
confirming the high expression of MSF observed by immunohistochemistry.
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Figure 45. Analysis of MSF mRNA expression by in situ  hybridization. Analysis of MSF mRNA 
expression in tissue sections derived from CHO-3E6 cells or control cells (CH0-A3). Panel a and a ’ are 
respectively the haematoxylin staining and ISH with the antisense riboprobe (AS) on sections from the 
control tumours; b and b ’ are haematoxylin staining and ISH with the sense riboprobe (S) on sections from 
CHO-3E6 tumours; c and c ’ and d and d ’ are haematoxylin staining and ISH with the antisense riboprobe on 
sections from CHO-3E6 tumours. Original magnification 20x.
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Figure 46. Analysis of MSF mRNA expression by in situ hybridization in human breast cancer.
Immunohistochemical analysis (a, b) and in situ hybridization (a’, b ’) o f human breast cancer: in panel a and 
a ’ is shown the negative control using the sense riboprobe (S); in panels b and b ’ is shown MSF mRNA in 
tumour tissue using the antisense riboprobe (AS).
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5 DISCUSSION
The aim of this work was to provide new insights on migration stimulating factor, a 
molecule produced by tumour-associated macrophages. Here we show the generation of 
new original reagents (recombinant protein, polyclonal and monoclonal antibodies) to 
study human recombinant MSF, a first characterization of the biological properties of the 
recombinant protein and the analysis of MSF expression in human tumours.
Much work has been done to characterize the role of TAMs in tumour biology, and a 
general consensus has now been reached in considering TAMs as strong supporters of 
tumour growth (Steidl et al, 2010). Recently Solinas et al. demonstrated that monocytes 
exposed to tumour-conditioned medium can acquire M2 polarization. In agreement, gene 
profiling data indicated that TAMs have an M2-like polarization. Taken together these 
observations suggest that the tumour itself can condition infiltrating macrophages to 
acquire a pro-tumoral M2-like phenotype. Among the genes selectively associated to M2 
polarization of macrophages is migration stimulating factor (Solinas et al, 2010).
MSF is an oncofetal isoform of human Fibronectin 1 originally described as expressed 
by fibroblasts, keratinocytes and vascular endothelial cells during the foetal life but not by 
healthy adult cells (Schor & Schor, 2010). The expression observed by us and by others 
(Deng et al, 2013; Schor & Schor, 2010) in tumor cells suggests that MSF could be part of 
the transcriptional program associated with neoplastic trasformation. This is also supported 
by the observation that M2-polarized pro-inflammatory and pro-tumoral macrophages can 
produce MSF, while Ml macrophages, that exert a strong tumoricidal activity, do not 
express this molecule. Accordingly with the theory that associates inflammation and 
cancer, it would be worthwhile to investigate whether MSF expression is up-regulated also 
in chronic inflammatory diseases from which cancer progression may occur.
The observation, made by gene profiling and confirmed in this study, of a selective 
expression of MSF by M2-like tumour associated macrophages accounts for our interest in
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this protein as potential marker for M2-like polarization. Since no commercial reagents 
were available to study MSF, considerable efforts were aimed at expressing and purifying 
recombinant human MSF and producing polyclonal and monoclonal antibodies 
recognizing this protein. Given the almost complete identity of MSF and FN1 and the high 
conservation of FN1 between humans and mice, the generation of antibodies was an 
important challenge and was made possible by outsourcing part of the activity. We 
obtained both polyclonal and monoclonal antibodies recognizing with specificity and a 
good sensitivity human MSF and not cross-reacting with FN1.
A second important issue was the production and purification of human MSF. Also in 
this case we took advantage of external partners that cloned the complete cDNA sequence 
of human MSF and helped in the setting up of the purification process. In addition we 
outsourced the production of His-MSF, a polypeptide comprising a hundred amino acids in 
the COOH terminal portion of MSF, including the specific decapeptide used as that is 
unique to MSF.
To evaluate the functional activity of purified MSF, we initially focused on its
motogenic properties. The recombinant MSF produced and purified during this project has
a motogenic activity for Panel cells used as a model system. Panel cells migrate to MSF
as much as to a standard motogenic stimulus represented by foetal calf serum. We
observed an heterogeneity in the migratory response of tumour cells, with the 8387
fibrosarcoma and a breast cancer cell line characterized by the highest motility, while, on
the contrary cell lines derived from colon cancer have a modest or no migratory response.
The same set of tumour cell lines was analysed by RT-qPCR to quantify MSF expression.
Interestingly, a significant correlation was observed between the levels of MSF mRNA
expression and the migratory capacity of the cell types analysed, suggesting that MSF
could act as an endogenous motility factor. This observation may have an important
implication for the process of metastasis formation, in fact tumor cell motility plays a vital
role in the process of tumor invasion and metastasis. In order to invade and metastasize,
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tumor cells must actively migrate out of the primary tumor and cross the extracellular 
matrix. Several substances, produced either by tumor or stromal cells, can stimulate cell 
locomotion, including for example members of the FGF family or cytokines such as 
granulocyte-macrophage colony stimulating factor (GM-CSF). A recent proteomic analysis 
of colorectal cancer (CRC) and non-tumorigenic tissues reveals a differential protein 
signature according to disease (CRC vs non-tumorigenic tissues) and stage (early vs late 
stage) (Sethi et al, 2015). Among the differentially expressed proteins, fibronectin showed 
the highest expression levels in CRC samples. Fibronectin is known to be involved in cell 
adhesion and migration (Pankov & Yamada, 2002), providing a pathway for stromal cell 
migration during embryogenesis, morphogenesis and wound healing. Similarly, fibronectin 
expression and deposition at sites of cancer can provide a path to tumor cells to move on. 
In this context it is tempting to speculate that MSF could exert a similar function, 
providing a road to tumor cells, thus favouring invasion and metastatization. This 
hypothesis needs to be confirmed by further experiments involving for instance the 
silencing of MSF in cancer cells.
The induction of a foetal-like migratory phenotype in adult fibroblasts is one of the 
properties of MSF that could be associated with neoplastic transformation (Schor & Schor, 
1987), thus it might be interesting to study the direct involvement of MSF in the induction 
of epithelial-mesenchymal transition. To this aim we are generating transfectants from 
Pane 1 cells, which express very low levels of endogenous MSF, to have cells lines with 
different capability to produce MSF. Once injected orthotopically in mouse pancreas, we 
could evaluate the incidence, growth rate and invasiveness of pancreatic cancer cell lines 
producing different levels of MSF. The monoclonal antibodies generated in this Thesis 
project were not tested jet as blocking antibody, but in the case one of them has this 
property it could be used to demonstrate the involvement of MSF in tumour progression.
The factors that could influence the heterogeneity in MSF mRNA expression by
different cancer cells are not known. It is known that M-CSF produced by tumour cells is
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responsible for MSF expression in macrophages exposed in vitro to tumour cell 
conditioned medium (Solinas et al, 2010). In addition cytokines promoting M2 polarization 
can regulate MSF expression in macrophages. TGF-p, a pro-tumoral cytokine mediating 
tumour-stroma interactions, has been described to induce MSF expression in fibroblasts 
from cancer patients or healthy subjects (Schor & Schor, 2010). We did not analyse the 
production of these mediators in our setting and in general further investigation on the 
regulation of MSF expression in tumour cells would likely be helpful to understand the 
relationship between MSF itself and cancer.
Beside tumour cells, we observed a significant migratory response of peripheral blood 
monocytes to recombinant MSF. Similarly to chemokines, MSF presents a characteristic 
bell-shape response curve and exerts its effect in the nanomolar range of concentration. An 
exhaustive analysis of target cells, i.e. lymphocytes, neutrophils, dendritic cells, is still 
missing and will be objective of further investigations. It has not been established jet 
whether MSF stimulates directional (chemotactic) and/or random (chemokinetic) motility 
of monocytes and tumor cells and no indications on a putative MSF receptor are available.
Several different integrins are described as putative receptor for fibronectin, such as 
a4pl, interacting with the IIICS region, and a5pl, interacting with the central region of 
FNL However the domains involved in the interaction of FN1 with integrins are not 
conserved in MSF. On the other side MSF maintains in its sequence some IGD motifs that 
are described to be motogenic (Schor et al, 1999) and to interact with avp3 integrin present 
in the focal adhesion (Millard et al, 2007). This interaction involves the tyrosine 
phosphorylation of focal adhesion kinase (ppFAK125) inducing an arrangement of the 
actin filaments in the cytoskeleton and consequently the migration. The RGD motifs 
present in fibronectin and not conserved in MSF also interact with avp3 integrin, but it is 
noteworthy to underline that interaction of RGD motifs with avp3 integrin results in loss 
and not in gain of motogenic activity, likely because of the inherent rigidity of these 
domains.
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The bell-shaped migratory response observed in our set of experiments suggest a 
possible analogy with chemokines, thus interaction of MSF with chemokine receptors also 
deserves further investigation using for instance transfected cells expressing a specific 
chemokine receptor or by means of blocking antibodies against different chemokine 
receptors.
We also found that human MSF can act on the murine system, stimulating migration of 
murine peritoneal macrophages. The optimal activity has been obtained with 1-0.1 ng/ml, a 
slightly higher concentration, but essentially comparable to what observed in human 
monocytes. A murine MSF has been identified (P. Brennecke et al, personal 
communication), characterized by the presence of a hypothetical dodecapeptide, instead of 
a decapeptide, at the C-terminus. The homology between the protein sequences of human 
MSF and the hypothetical murine counterpart is approximately 92,7%. The few 
mismatches between the two molecules are located in the motogenic domain (Gel-BD) of 
the protein. This could be likely responsible for the different efficiency in terms of 
motogenic activity of human MSF on human or mouse macrophages. This observation 
suggests that, even if with several limitations, the murine model can be used to test the 
biological role of MSF in tumours.
To evaluate a pro-tumoral role of MSF we investigated the in vivo growth rates of
tumours derived from cells expressing or not human MSF. Injection of transfected cells
expressing MSF into CB 17/SCID mice led to the development of tumours with higher
growth rate compared to the control counterparts. It has been described that MSF does not
exert mitogenic effects on tumour cells (Deng et al, 2013), and we confirm this observation
on our MSF-expressing CHO cells and CHO-WT cells. Thus, given the migratory effect of
MSF on monocytes, an obvious mechanism to explain the higher growth rate observed in
vivo was the possible attraction and accumulation of TAMs. However, when tumour
sections were analysed by immunohistochemistry, we did not observe any difference in the
percentage of macrophages infiltrating the experimental tumours. In the same setting the
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evaluation of angiogenesis did not evidenced any significant difference between tumours 
expressing or not MSF. This latter observation need further investigation since a 
proangiogenic role is described for MSF. We could not exclude the release by stromal cells 
of other angiogenic factors that could overcome the presence or not of MSF. Subcutaneous 
injection of MSF expressing cells in a matrigel will probably allow better to define the pro­
angiogenic role of MSF protein.
The observations in this setting indicate that macrophage infiltration is not sufficient to 
explain the higher tumour growth rate observed in vivo. Even if we did not observe any 
difference in the in vitro growth rate of cells expressing or not MSF, we could not exclude 
a direct effect of MSF in vivo on tumour or stromal cells, for istance promoting the release 
of growth factors. In addition a skewing of Ml to M2 polarized macrophages could 
eventually determine the differences observed in the growth rate. Thus the mechanisms 
involved in the growth differences observed in vivo need further investigations.
The observation that MSF was expressed by different tumour cell lines as well as 
by M2-like TAMs, prompted us to analyse MSF expression in histological sections derived 
from human cancers. We found an extensive staining with MoAbElO, recognizing human 
MSF, in breast, lung and colon cancers, regarding tumour, stromal and endothelial cells. In 
situ hybridization confirmed the high level of MSF expression in tumour sections. The 
immunohistochemical analysis also confirmed the positivity of a proportion of infiltrating 
macrophages identified by the expression of CD68. These observations indicate that the 
anti MSF antibodies generated here can be used to identify sub-population of TAMs, likely 
M2-like TAMs, and to follow the changes over the time for this population. As a matter of 
fact pre-clinical studies demonstrate that re-education of TAMs can endow them with the 
capacity to kill tumour cells (Duluc et al, 2009; Mantovani et al, 2014), thus more often 
TAMs are target for therapeutic approaches aimed to their re-education (Getts et al, 2014).
While an extensive staining for MSF was observed in lung and breast tumour
specimens, a more heterogeneous immunostaining was seen in colon cancer sections, in
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agreement with the lower MSF expression observed in colon cancer cell lines. In this 
regards, infiltrating macrophages in colon cancer represent an exception in the field of 
tumour-associated macrophages. In fact contrasting results are reported, with some 
observations reporting the association of TAMs with a poor prognosis, while in other cases 
TAMs infiltrating colon cancers have a protective role (reviewed in (Erreni et al, 2011; 
Mantovani & Allavena, 2015). This suggests again the importance of tumour 
microenvironment in determining the polarization of macrophages and the effects this may 
have on the production of soluble mediators such as MSF.
The presence of MSF in the serum of breast cancer patients has been demonstrated 
previously using a bioassay for the measurement of migration stimulating activity for 
fibroblasts (Picardo et al, 1991). Apart from this bioassay, no systems for the measurement 
of MSF levels in biological fluids are available. Therefore, we set up a sandwich ELISA 
using a combination of anti FN1 and rabbit polyclonal anti-MSF antibodies. With this 
system we were able to measure MSF in plasma better that in serum of healthy volunteers. 
This observation potentially represent an important proof-of-principle of the possibility to 
measure MSF in biological fluids. Ongoing efforts are directed to investigate whether MSF 
could be a marker of neoplastic transformation in humans.
TAMs exert several pro-tumoral functions, promoting tumour proliferation, 
angiogenesis, immune suppression, tissue remodelling and metastasis, and eventually also 
resistance to therapy (Biswas & Mantovani, 2010; Mantovani et al, 2014; Pollard, 2004). 
MSF is produced by M2-like TAM and is upregulated both in cancer and stromal cells, 
thus is part of the tumoral microenvironment. In addition, expression by M2-like pro- 
tumoral TAMs suggests that MSF could represent an attractive marker of M2 polarization. 
Given that TAMs are promising target for anticancer therapy, the development of an 
antibody that can identify M2 polarized cells would be of considerable interest.
In the era of personalized medicine the tailoring of medical treatments to the
individual characteristics is acquiring more and more relevance in the set-up of new
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therapeutic strategies. In this context the possibility to identify M2 polarized macrophages 
infiltrating a tumor may have a particular relevance. To this aim it would be interesting to 
perform an extensive immunohystochemical analysis on human tumors with different 
origin in order to evaluate the levels of M2 polarized, MSF-expressing tumor associated 
macrophages. This could allow to obtain a “molecular profile” for each patient by 
combining the levels of MSF in biological fluids, evaluated with a sandwich ELISA to be 
developed, and the immunohistochemical evaluation of M2-polarized TAMs. Thus MSF 
could have a significant diagnostic e prognostic value. MSF levels could also be analysed 
in relation to tumour staging or on the basis of the chemotherapeutic treatment of patients, 
in order to correlate MSF expression with tumour progression. On the basis of these 
analysis we expect to define whether MSF could represent a useful marker for tumour 
progression.
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